US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6300129B1
(en)
*
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US5795966A
(en)
†
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
EP1978033A3
(en)
*
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
AU2466895A
(en)
*
|
1995-04-28 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6632976B1
(en)
|
1995-08-29 |
2003-10-14 |
Kirin Beer Kabushiki Kaisha |
Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
WO1997039775A1
(fr)
|
1996-04-23 |
1997-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Medicament pour le traitement ou la prevention des accidents vasculaires cerebraux/de l'×deme cerebral, contenant comme principe actif un inhibiteur de la fixation de l'il-8
|
CZ106299A3
(cs)
|
1996-09-26 |
1999-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
|
KR100942002B1
(ko)
*
|
1996-12-03 |
2010-02-12 |
암젠 프레몬트 인코포레이티드 |
복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
|
AU2450102A
(en)
*
|
1996-12-03 |
2002-08-08 |
Abgenix, Inc. |
Transgenic mammals having human IG LOCI including plural Vh and Vk regions and antibodies produced therefrom
|
KR100838862B1
(ko)
|
1997-03-21 |
2008-06-16 |
츄가이 세이야꾸 가부시키가이샤 |
아이엘-6 안타고니스트를 유효성분으로 함유하는 감작 티 세포 관여 질환의 예방 또는 치료제
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
KR100508338B1
(ko)
|
1997-05-15 |
2005-08-17 |
츄가이 세이야꾸 가부시키가이샤 |
악액질 치료제
|
PT1004315E
(pt)
|
1997-08-15 |
2008-07-09 |
Chugai Pharmaceutical Co Ltd |
Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico
|
WO1999027105A2
(en)
|
1997-11-21 |
1999-06-03 |
Genset |
Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
EP2228385A1
(en)
|
1997-11-28 |
2010-09-15 |
Merck Serono Biodevelopment |
Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
CN100374159C
(zh)
|
1998-03-17 |
2008-03-12 |
中外制药株式会社 |
一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
|
US20020029391A1
(en)
*
|
1998-04-15 |
2002-03-07 |
Claude Geoffrey Davis |
Epitope-driven human antibody production and gene expression profiling
|
EP1115863B1
(en)
*
|
1998-09-22 |
2007-11-28 |
Genentech, Inc. |
Ucp4
|
ATE518950T1
(de)
|
1998-11-04 |
2011-08-15 |
Chugai Pharmaceutical Co Ltd |
Neue serinproteasen der trypsin-familie
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
JP3793693B2
(ja)
*
|
1998-12-23 |
2006-07-05 |
ファイザー インコーポレーテッド |
Ctla−4に対するヒトモノクローナル抗体
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
AU2907200A
(en)
*
|
1999-02-05 |
2000-08-25 |
Jens-Ulrich Bulow |
Human polyclonal antibodies from genetically engineered animals
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
MY145191A
(en)
|
1999-03-25 |
2011-12-30 |
Abbott Gmbh & Co Kg |
Human antibodies that bind human il-12 and methods for producing
|
WO2000061744A1
(fr)
|
1999-04-09 |
2000-10-19 |
Chugai Research Institute For Molecular Medicine, Inc. |
Nouveaux genes de foetus
|
EP2325316B8
(en)
|
1999-06-02 |
2017-04-19 |
Chugai Seiyaku Kabushiki Kaisha |
Novel hemopoietin receptor protein, NR10
|
CA2373885A1
(en)
*
|
1999-07-02 |
2001-01-11 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for diseases caused by pth or pthrp
|
TWI255718B
(en)
|
1999-07-02 |
2006-06-01 |
Chugai Pharmaceutical Co Ltd |
Ameliorative agent for low vasopressin concentration
|
RU2002102916A
(ru)
*
|
1999-07-06 |
2003-11-10 |
Чугаи Сейяку Кабусики Кайся (Jp) |
Терапевтический агент для лечения устойчивой к лекраственным препаратам гиперкальциемии
|
KR20020025990A
(ko)
|
1999-08-23 |
2002-04-04 |
나가야마 오사무 |
에이치엠1.24 항원의 발현 증강제
|
EP1212422B1
(en)
*
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
AU6871900A
(en)
|
1999-09-06 |
2001-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Tsg-like gene
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
AU7317400A
(en)
|
1999-09-21 |
2001-04-24 |
Chugai Research Institute For Molecular Medicine, Inc. |
Transporter genes oatp-b, c, d and e
|
EP1222854B1
(en)
|
1999-10-01 |
2011-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
US6794132B2
(en)
*
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
US7135287B1
(en)
|
1999-10-02 |
2006-11-14 |
Biosite, Inc. |
Human antibodies
|
US6680209B1
(en)
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
US20030124119A1
(en)
*
|
1999-12-28 |
2003-07-03 |
Tadao Yamazaki |
Stable antibody compositions and injection preparations
|
EP1251172B1
(en)
|
2000-01-24 |
2008-10-01 |
Haruo Sugiyama |
Wt1-interacting protein wtip
|
WO2001054725A1
(fr)
*
|
2000-01-25 |
2001-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Remèdes et agents prophylactiques pour maladies dentaires
|
EP2338515A3
(en)
|
2000-02-10 |
2011-11-16 |
Abbott Laboratories |
Antibodies that bind human interleukin-18 and methods of making and using
|
US6653448B1
(en)
|
2000-03-29 |
2003-11-25 |
Curagen Corporation |
Wnt-7B-like polypeptides and nucleic acids encoding same
|
CA2401357A1
(en)
*
|
2000-02-28 |
2001-09-07 |
Chugai Seiyaku Kabushiki Kaisha |
Tissue degradation inhibitor agent
|
GB0006398D0
(en)
*
|
2000-03-16 |
2000-05-03 |
Novartis Ag |
Organic compounds
|
ES2484966T3
(es)
|
2000-04-12 |
2014-08-12 |
Novozymes Biopharma Dk A/S |
Proteínas de fusión de albúmina
|
AU2001259215A1
(en)
*
|
2000-04-28 |
2001-11-12 |
La Jolla Institute For Allergy And Immunology |
Human anti-cd40 antibodies and methods of making and using same
|
EP1987842A1
(en)
|
2000-04-28 |
2008-11-05 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitor
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
ES2192426B1
(es)
*
|
2000-05-11 |
2005-02-16 |
Universidad De Vigo |
Anticuerpo monoclonal humano sm50/20 que reconoce leucocitos humanos, y su uso en terapia.
|
MXPA02011682A
(es)
|
2000-05-26 |
2003-05-14 |
Immunex Corp |
Uso de antagonistas de interleuquina-4 y composiciones de los mismos.
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
|
WO2002002641A1
(en)
|
2000-06-16 |
2002-01-10 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to blys
|
WO2002000724A2
(en)
|
2000-06-28 |
2002-01-03 |
Amgen, Inc. |
Thymic stromal lymphopoietin receptor molecules and uses thereof
|
SK1152003A3
(en)
|
2000-06-29 |
2003-07-01 |
Abbott Lab |
Dual specificity antibodies and methods of making and using
|
US6902734B2
(en)
*
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
*
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
UA81743C2
(uk)
*
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
AU8886601A
(en)
*
|
2000-09-07 |
2002-03-22 |
John R Schreiber |
Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
|
CN1259973C
(zh)
|
2000-10-25 |
2006-06-21 |
中外制药株式会社 |
含有il-6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
|
NZ525664A
(en)
|
2000-11-17 |
2008-08-29 |
Kirin Holdings Kk |
Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
|
CA2430039C
(en)
|
2000-11-28 |
2014-01-28 |
Medimmune, Inc. |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
EP1415005B1
(en)
|
2000-12-07 |
2012-11-21 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
WO2002060919A2
(en)
|
2000-12-12 |
2002-08-08 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
MX337162B
(es)
*
|
2001-01-05 |
2016-02-15 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
|
WO2002064159A1
(en)
|
2001-02-07 |
2002-08-22 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for tumor in hematopoietic organs
|
EP1366058B1
(en)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
JP2005508608A
(ja)
|
2001-03-22 |
2005-04-07 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
問題遺伝子に対して特異的な抗体を発現するトランスジェニック動物及びその使用
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
ES2192128B1
(es)
*
|
2001-04-27 |
2005-01-01 |
Universidad De Vigo |
Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
|
CN101508734A
(zh)
|
2001-04-27 |
2009-08-19 |
协和发酵麒麟株式会社 |
抗cd40单克隆抗体
|
WO2002092017A2
(en)
|
2001-05-16 |
2002-11-21 |
Albert Einstein College Of Medicine Of Yeshiva University |
Human antipneumococcal antibodies from non-human animals
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
KR20080077295A
(ko)
|
2001-06-22 |
2008-08-21 |
츄가이 세이야꾸 가부시키가이샤 |
항글리피칸 3항체를 포함하는 세포증식 억제제
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
ES2645698T3
(es)
|
2001-11-30 |
2017-12-07 |
Amgen Fremont Inc. |
Animales transgénicos que portan genes de cadena ligera de Ig humana
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR101080021B1
(ko)
|
2002-02-14 |
2011-11-04 |
추가이 세이야쿠 가부시키가이샤 |
항체함유 용액제제
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
JP2005520543A
(ja)
|
2002-03-21 |
2005-07-14 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における新規組成物および方法
|
ATE435239T1
(de)
|
2002-03-29 |
2009-07-15 |
Schering Corp |
Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
|
JPWO2003083116A1
(ja)
|
2002-03-29 |
2005-08-04 |
中外製薬株式会社 |
トランスポーター阻害物質スクリーニング方法
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
MXPA04010013A
(es)
|
2002-04-12 |
2004-12-13 |
Medarex Inc |
Metodos de tratamiento utilizando anticuerpos al antigeno-4 asociado con el linfocito t citotoxico.
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
GB0208817D0
(en)
*
|
2002-04-17 |
2002-05-29 |
European Molecular Biology Lab Embl |
Method for producing monoclonal antibodies
|
JP2005525817A
(ja)
|
2002-05-17 |
2005-09-02 |
ヘマテック,エルエルシー |
ヒト抗体産生が可能なトランスジェニック有蹄動物
|
ES2361541T3
(es)
|
2002-06-06 |
2011-06-17 |
Oncotherapy Science, Inc. |
Genes y polipéptidos relacionados con cánceres de colon humanos.
|
DE60336227D1
(de)
|
2002-06-06 |
2011-04-14 |
Oncotherapy Science Inc |
Gene und proteine mit bezug zu menschlichem kolonkrebs
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
JP4776228B2
(ja)
|
2002-07-15 |
2011-09-21 |
ワイス・エルエルシー |
Tヘルパー(th)細胞の発生および機能を調節するための方法および組成物
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
JP4489591B2
(ja)
|
2002-08-27 |
2010-06-23 |
中外製薬株式会社 |
タンパク質溶液製剤の安定化方法
|
US7438910B2
(en)
|
2002-09-06 |
2008-10-21 |
Amgen Inc. |
Therapeutic human anti-IL1-R1 monoclonal antibody
|
JP2006516383A
(ja)
|
2002-09-09 |
2006-07-06 |
デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド |
Bh3ペプチドおよびその使用方法
|
CA2497364C
(en)
|
2002-09-11 |
2013-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Protein purification method
|
TW200413725A
(en)
|
2002-09-30 |
2004-08-01 |
Oncotherapy Science Inc |
Method for diagnosing non-small cell lung cancers
|
TW200418988A
(en)
|
2002-09-30 |
2004-10-01 |
Oncotherapy Science Inc |
Method for diagnosing prostate cancer
|
EP3284753B1
(en)
|
2002-10-17 |
2019-06-05 |
Genmab A/S |
Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
|
SG146441A1
(en)
|
2002-10-22 |
2008-10-30 |
Eisai R&D Man Co Ltd |
Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
|
AU2003280643A1
(en)
|
2002-10-30 |
2004-05-25 |
Chugai Seiyaku Kabushiki Kaisha |
Membrane protein originating in mast cells
|
EP1563084A4
(en)
|
2002-11-08 |
2006-03-01 |
Hematech Llc |
TRANSGENE UNGULATES WITH REDUCED PRION PROTEIN ACTIVITY AND USES THEREOF
|
WO2004045532A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
EP1660535A2
(en)
|
2002-11-27 |
2006-05-31 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
NZ541050A
(en)
|
2002-12-16 |
2010-06-25 |
Genmab As |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
JP3955885B2
(ja)
|
2002-12-29 |
2007-08-08 |
日産化学工業株式会社 |
アディポネクチン受容体及びそれをコードする遺伝子
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
AU2004212953B2
(en)
|
2003-02-14 |
2010-03-11 |
The Curators Of The University Of Missouri |
Contraceptive methods and compositions related to proteasomal interference
|
JP2007524362A
(ja)
|
2003-02-14 |
2007-08-30 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における治療gpcr標的
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
ES2537015T3
(es)
|
2003-03-19 |
2015-06-01 |
Biogen Ma Inc. |
Proteína de unión del receptor de NOGO
|
EP1613273B1
(en)
|
2003-04-11 |
2012-06-13 |
MedImmune, LLC |
Recombinant il-9 antibodies and uses thereof
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
ES2527871T3
(es)
*
|
2003-05-01 |
2015-02-02 |
Imclone Llc |
Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
|
US20070025961A1
(en)
*
|
2003-06-03 |
2007-02-01 |
Kenzo Bamba |
Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
|
JPWO2005017155A1
(ja)
|
2003-06-18 |
2006-10-12 |
中外製薬株式会社 |
フコーストランスポーター
|
MXPA06000583A
(es)
|
2003-07-15 |
2006-03-30 |
Amgen Inc |
Anticuerpos neutralizantes anti-ngf humano como inhibidores selectivos de la via del ngf.
|
CA2532250A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases
|
PL1648998T3
(pl)
*
|
2003-07-18 |
2015-03-31 |
Amgen Inc |
Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
ATE528397T1
(de)
|
2003-08-08 |
2011-10-15 |
Perseus Proteomics Inc |
Bei krebs überexprimiertes gen
|
WO2005014854A1
(en)
|
2003-08-08 |
2005-02-17 |
Licentia, Ltd. |
Materials and methods for colorectal cancer screening, diagnosis, and therapy
|
US20050221383A1
(en)
|
2003-08-08 |
2005-10-06 |
Choong-Chin Liew |
Osteoarthritis biomarkers and uses thereof
|
EA200600234A1
(ru)
|
2003-08-13 |
2006-08-25 |
Пфайзер Продактс Инк. |
Модифицированные igf - 1r антитела человека
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP2311945A1
(en)
|
2003-10-14 |
2011-04-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibodies substituting for functional proteins
|
CA2543982C
(en)
|
2003-11-07 |
2013-01-08 |
Immunex Corporation |
Antibodies that bind interleukin-4 receptor
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
CN1914226B
(zh)
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
SARS-CoV抗体及其使用方法
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
US20090041659A1
(en)
|
2003-12-05 |
2009-02-12 |
Schreiber John R |
Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse
|
DE602004020266D1
(de)
|
2003-12-05 |
2009-05-07 |
Multimmune Gmbh |
Therapeutische und diagnostische anti-hsp 70-antikörper
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
HUE064610T2
(hu)
|
2003-12-23 |
2024-04-28 |
Genentech Inc |
Új anti-IL 13 antitestek és alkalmazásaik
|
CN107090034B
(zh)
|
2004-01-07 |
2021-10-01 |
诺华疫苗和诊断公司 |
M-csf特异性单克隆抗体及其应用
|
SV2006001990A
(es)
|
2004-01-09 |
2006-01-30 |
Pfizer |
Anticuerpos contra madcam
|
PL1729795T3
(pl)
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Białka fuzyjne albuminy
|
EP2343384A3
(en)
|
2004-03-23 |
2012-01-04 |
Oncotherapy Science, Inc. |
Method for diagnosing non-small cell lung cancer
|
CA2562771C
(en)
|
2004-04-12 |
2013-04-09 |
Medimmune, Inc. |
Anti-il-9 antibody formulations and uses thereof
|
EP1749102A4
(en)
|
2004-04-22 |
2009-02-25 |
Kirin Pharma Kk |
TRANSGENIC ANIMALS AND USES THEREOF
|
US7491868B2
(en)
*
|
2004-04-30 |
2009-02-17 |
The General Hospital Corporation |
Mannose binding lectin knock-out mice and methods of use thereof
|
US8492106B2
(en)
|
2004-05-24 |
2013-07-23 |
Universitat Zu Koln |
Identification methods for ergothioneine transporter modulators and therapeutic uses thereof
|
ES2552774T3
(es)
|
2004-06-01 |
2015-12-02 |
Icahn School Of Medicine At Mount Sinai |
Virus de la gripe porcina modificado por ingeniería genética y usos de los mismos
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
BRPI0512500A
(pt)
|
2004-06-24 |
2008-03-11 |
Biogen Idec Inc |
tratamento ou condições envolvendo desmielinação
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
EP2335727A3
(en)
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
CA2574177C
(en)
|
2004-07-22 |
2019-01-08 |
Eisai Co., Ltd. |
Lrp4/corin dopaminergic neuron progenitor cell markers
|
EP1789070B1
(en)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Taj in neuronal function
|
ES2414460T3
(es)
|
2004-08-04 |
2013-07-19 |
Amgen Inc. |
Anticuerpos para Dkk-1
|
BRPI0514395A
(pt)
|
2004-08-16 |
2008-06-10 |
Quark Biotech Inc |
uso terapêutico de inibidores de rtp801
|
AU2004224925C1
(en)
|
2004-08-30 |
2011-07-21 |
Biotest Ag |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
EP3073267A1
(en)
|
2004-09-21 |
2016-09-28 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
CA2582683A1
(en)
|
2004-10-01 |
2006-04-13 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Novel antibodies directed to the mammalian eag1 ion channel protein
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
KR20070085439A
(ko)
|
2004-12-06 |
2007-08-27 |
기린 비루 가부시키가이샤 |
인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법
|
NZ583153A
(en)
|
2004-12-21 |
2011-06-30 |
Centocor Ortho Biotech Inc |
Anti-IL-12 antibodies, epitopes, compositions, methods and uses
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
JPWO2006067847A1
(ja)
|
2004-12-22 |
2008-06-12 |
中外製薬株式会社 |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
TWI441646B
(zh)
|
2005-01-21 |
2014-06-21 |
Genentech Inc |
帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
|
PA8660701A1
(es)
|
2005-02-04 |
2006-09-22 |
Pfizer Prod Inc |
Agonistas de pyy y sus usos
|
EP2520669A3
(en)
|
2005-02-07 |
2013-02-27 |
GeneNews Inc. |
Mild osteoathritis biomarkers and uses thereof
|
EP1856278A2
(en)
|
2005-02-10 |
2007-11-21 |
Oncotherapy Science, Inc. |
Method of diagnosing bladder cancer
|
BRPI0608210A2
(pt)
|
2005-02-14 |
2010-11-09 |
Wyeth Corp |
métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina
|
BRPI0606991A2
(pt)
|
2005-02-14 |
2009-08-18 |
Wyeth Corp |
métodos para triar compostos de teste capazes de antagonizar a sinalização de il-17f, para diagnosticar um distúrbio relacionado com a sinalização aumentada de il-17f em um indivìduo, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-21, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-23, para purificar a proteìna il-17a natural, e para isolar heterodìmeros de il-17 a/il-17f substancialmente isentos de homodìmeros de il-17a e homodìmeros de il-17f, uso de uma quantidade terapeuticamente eficaz de um antagonista da sinalização de il-17f, composição farmacêutica, adjuvante de vacina, anticorpo isolado, proteìnas il-17f e il-17a isoladas, e, heterodìmero de il-17a/il-17f
|
DK1853718T3
(en)
|
2005-02-15 |
2015-11-09 |
Univ Duke |
ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
|
WO2006089141A2
(en)
|
2005-02-18 |
2006-08-24 |
Dana-Farber Cancer Institute |
Antibodies against cxcr4 and methods of use thereof
|
TWI406870B
(zh)
|
2005-02-21 |
2013-09-01 |
Chugai Pharmaceutical Co Ltd |
A method of making a protein using hamster IGF-1
|
CN101163503B
(zh)
|
2005-02-23 |
2013-05-08 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
US8211430B2
(en)
|
2005-03-04 |
2012-07-03 |
Curedm Group Holdings, Llc |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
BRPI0608815B1
(pt)
|
2005-03-08 |
2021-10-13 |
Pfizer Products Inc |
Composições de anticorpo anti-ctla-4
|
DK1875244T3
(en)
|
2005-03-30 |
2019-04-29 |
Minerva Biotechnologies Corp |
Proliferation of MUC1-Expressing Cells
|
EP1875244B1
(en)
|
2005-03-30 |
2019-01-23 |
Minerva Biotechnologies Corporation |
Proliferation of muc1 expressing cells
|
DK3050963T3
(da)
|
2005-03-31 |
2019-12-09 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
|
AU2006235276A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
CACNA1E in cancer diagnosis, detection and treatment
|
CA2604844A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics, Inc. |
Cancer-related genes
|
PT1876236E
(pt)
|
2005-04-08 |
2014-10-22 |
Chugai Pharmaceutical Co Ltd |
Anticorpos para substituição da função do factor de coagulação sanguínea viii
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
US9889197B2
(en)
|
2005-04-15 |
2018-02-13 |
Macrogenics, Inc. |
Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
|
ES2971647T3
(es)
|
2005-04-15 |
2024-06-06 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
CA2605964A1
(en)
|
2005-04-20 |
2006-10-26 |
Amgen Fremont Inc. |
High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
|
AU2006239860B2
(en)
|
2005-04-25 |
2012-01-19 |
Amgen Fremont Inc. |
Antibodies to myostatin
|
BRPI0608096A2
(pt)
|
2005-04-26 |
2009-11-10 |
Pfizer |
anticorpos p-caderina
|
JP5047947B2
(ja)
|
2005-05-05 |
2012-10-10 |
デューク ユニバーシティ |
自己免疫疾患のための抗cd19抗体治療
|
US8124084B2
(en)
|
2005-05-17 |
2012-02-28 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
|
EP1883417A2
(en)
|
2005-05-25 |
2008-02-06 |
Curedm Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
CA2609600C
(en)
|
2005-05-27 |
2016-11-08 |
Biogen Idec Ma Inc. |
Tweak binding antibodies
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
JP2008543335A
(ja)
*
|
2005-06-22 |
2008-12-04 |
ジェネンテック・インコーポレーテッド |
Ifnar2を標的とするための方法と組成物
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
JP2009502123A
(ja)
|
2005-07-08 |
2009-01-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Sp35抗体およびその使用
|
JP2009502114A
(ja)
|
2005-07-27 |
2009-01-29 |
オンコセラピー・サイエンス株式会社 |
前立腺癌に関連する遺伝子およびポリペプチド
|
US8652469B2
(en)
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
JP5230420B2
(ja)
|
2005-08-18 |
2013-07-10 |
ゲンマブ エー/エス |
Cd4結合ペプチドおよび放射線による治療
|
EP1928506A4
(en)
|
2005-08-19 |
2009-10-21 |
Abbott Lab |
IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
SI1915397T1
(sl)
|
2005-08-19 |
2015-05-29 |
Wyeth Llc |
Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
|
TWI370137B
(en)
|
2005-09-07 |
2012-08-11 |
Amgen Fremont Inc |
Human monoclonal antibodies to activin receptor-like kinase-1
|
WO2007039256A2
(de)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
CA2625773C
(en)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
TW200730825A
(en)
|
2005-10-21 |
2007-08-16 |
Genenews Inc |
Method and apparatus for correlating levels of biomarker products with disease
|
KR101239051B1
(ko)
|
2005-10-21 |
2013-03-04 |
추가이 세이야쿠 가부시키가이샤 |
심장질환 치료제
|
CA2628451A1
(en)
|
2005-11-04 |
2007-05-18 |
Biogen Idec Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
CA2903896A1
(en)
|
2005-11-04 |
2007-05-18 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
AU2006311661B2
(en)
|
2005-11-07 |
2011-05-26 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
JP5398987B2
(ja)
|
2005-11-14 |
2014-01-29 |
セルミド リミテッド |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
EA015526B1
(ru)
|
2005-11-14 |
2011-08-30 |
Ринат Ньюросайенс Корп. |
Антагонистические антитела против пептида, связанного с геном кальцитонина, и способы их применения
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
JPWO2007061029A1
(ja)
|
2005-11-25 |
2009-05-07 |
学校法人慶應義塾 |
前立腺癌治療剤
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
DK1963369T3
(da)
|
2005-11-28 |
2013-06-03 |
Zymogenetics Inc |
Il-21-antagonister
|
BRPI0619249A2
(pt)
|
2005-11-30 |
2011-09-20 |
Abbott Lab |
anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
|
RU2432362C2
(ru)
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
EP2543384A3
(en)
|
2005-12-02 |
2013-04-10 |
Biogen Idec MA Inc. |
Treatment of conditions involving demyelination
|
AP2911A
(en)
|
2005-12-02 |
2014-05-31 |
Sinai School Medicine |
Chimeric Viruses presenting non-native surface proteins and uses thereof
|
US8466263B2
(en)
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
EP1954719A2
(en)
|
2005-12-02 |
2008-08-13 |
Genentech Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
AU2006321593B2
(en)
|
2005-12-07 |
2012-10-04 |
E. R. Squibb & Sons, L.L.C. |
CTLA-4 antibody dosage escalation regimens
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルgm1に対するヒトモノクローナル抗体および抗フコシルgm1を使用するための方法
|
EP2325208B1
(en)
|
2005-12-15 |
2017-09-20 |
Genentech, Inc. |
Polyubiquitin antibodies
|
BRPI0619853A2
(pt)
*
|
2005-12-15 |
2016-08-23 |
Astrazeneca Ab |
combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
STABILIZER PREPARATION CONTAINING ANTIBODIES
|
ES2524015T3
(es)
|
2005-12-30 |
2014-12-03 |
Dyax Corporation |
Proteínas de enlazamiento a la metaloproteinasa
|
NL2000439C2
(nl)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutische toepassingen van inhibitoren van RTP801.
|
WO2007086490A1
(ja)
|
2006-01-27 |
2007-08-02 |
Keio University |
脈絡膜血管新生を伴う疾患の治療剤
|
CN103215293B
(zh)
|
2006-01-27 |
2015-10-28 |
比奥根Ma公司 |
Nogo受体拮抗剂
|
ATE491948T1
(de)
|
2006-02-06 |
2011-01-15 |
Rhode Island Hospital |
Gpr30-östrogenrezeptor bei mammakarzinomen
|
WO2007106448A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Lexicon Genetics Incorporated |
Methods for making antibodies in genetically engineered mice
|
EP2010569A4
(en)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
FOR GASTRIN SPECIFIC HUMAN ANTIBODIES, MATERIALS AND METHODS
|
CA2638774C
(en)
|
2006-03-31 |
2015-11-24 |
Medarex, Inc. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
CN105177091A
(zh)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
CA2645853A1
(en)
|
2006-03-31 |
2007-11-01 |
Dana-Farber Cancer Institute |
Methods of determining cellular chemosensitivity
|
AU2007232873B2
(en)
|
2006-03-31 |
2014-02-20 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
CA2648644C
(en)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Muscle regeneration promoter
|
EP2407483A1
(en)
|
2006-04-13 |
2012-01-18 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancers
|
WO2007119796A1
(ja)
|
2006-04-14 |
2007-10-25 |
Medical And Biological Laboratories Co., Ltd. |
エフェクター機能を有するポリペプチド変異体
|
SG172656A1
(en)
|
2006-05-30 |
2011-07-28 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
MX2008015541A
(es)
|
2006-06-06 |
2008-12-18 |
Genentech Inc |
Anticuerpos anti-dll4 y metodos que los usan.
|
MX2008015568A
(es)
|
2006-06-08 |
2009-01-13 |
Chugai Pharmaceutical Co Ltd |
Agentes para prevenir o tratar enfermedades inflamatorias.
|
US9056906B2
(en)
|
2006-06-14 |
2015-06-16 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP5248494B2
(ja)
|
2006-07-11 |
2013-07-31 |
ユニバーシティ・オブ・メディシン・アンド・デンティストリー・オブ・ニュージャージー |
タンパク質、それをコードする核酸および関連する使用方法
|
CA2657385A1
(en)
|
2006-07-13 |
2008-01-17 |
Naoki Kimura |
Cell death inducer
|
KR101528939B1
(ko)
|
2006-07-18 |
2015-06-15 |
사노피 |
암 치료를 위한 epha2에 대한 길항제 항체
|
JP5175729B2
(ja)
|
2006-07-21 |
2013-04-03 |
中外製薬株式会社 |
腎疾患治療剤
|
KR20090058512A
(ko)
|
2006-08-04 |
2009-06-09 |
아스트라제네카 아베 |
Erbb2에 대한 인간 항체
|
US8586716B2
(en)
|
2006-08-04 |
2013-11-19 |
Novartis Ag |
EPHB3-specific antibody and uses thereof
|
WO2008020586A1
(en)
|
2006-08-14 |
2008-02-21 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
|
GEP20125612B
(en)
|
2006-08-18 |
2012-08-27 |
Novartis Ag |
Prlr-specific antibody and usage thereof
|
KR101374983B1
(ko)
|
2006-08-28 |
2014-03-17 |
라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 |
길항성 인간 light-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
PE20081216A1
(es)
*
|
2006-09-01 |
2008-09-04 |
Therapeutic Human Polyclonals Inc |
Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
|
US20090053210A1
(en)
|
2006-09-01 |
2009-02-26 |
Roland Buelow |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
WO2008127271A2
(en)
|
2006-09-08 |
2008-10-23 |
Abbott Laboratories |
Interleukin -13 binding proteins
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
US20100297103A1
(en)
|
2006-09-14 |
2010-11-25 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
EP2099467B1
(en)
|
2006-10-03 |
2017-05-10 |
University Of Medicine And Dentistry Of New Jersey |
Atap peptides, nucleic acids encoding the same and associated methods of use
|
CA2664567C
(en)
|
2006-10-04 |
2016-04-26 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
EP2076287A2
(en)
|
2006-10-12 |
2009-07-08 |
Wyeth |
Methods and compositions with reduced opalescence
|
WO2008047723A1
(en)
|
2006-10-12 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-ereg antibody
|
WO2008048545A2
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
JP5378795B2
(ja)
|
2006-10-20 |
2013-12-25 |
中外製薬株式会社 |
抗hb−egf抗体を有効成分として含む医薬組成物
|
AU2007311946A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
|
DK2845866T3
(en)
|
2006-10-27 |
2017-07-10 |
Genentech Inc |
Antibodies and immunoconjugates and their applications
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
AU2007315211B2
(en)
|
2006-11-03 |
2013-01-17 |
U3 Pharma Gmbh |
FGFR4 antibodies
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
WO2008152446A2
(en)
|
2006-11-27 |
2008-12-18 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
AU2007329307B2
(en)
|
2006-12-07 |
2012-08-02 |
Novartis Ag |
Antagonist antibodies against EphB3
|
US20100111852A1
(en)
|
2006-12-14 |
2010-05-06 |
Forerunner Pharma Research Co., Ltd. |
Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
|
TWI419904B
(zh)
|
2006-12-18 |
2013-12-21 |
Genentech Inc |
拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
|
CA2673592C
(en)
|
2006-12-20 |
2014-03-25 |
Xoma Technology Ltd. |
Methods for the treatment of il-1.beta. related diseases
|
US20100111851A1
(en)
|
2007-01-05 |
2010-05-06 |
The University Of Tokyo |
Diagnosis and treatment of cancer by using anti-prg-3 antibody
|
CN101622275B
(zh)
|
2007-01-05 |
2013-11-06 |
苏黎世大学 |
提供疾患特异性结合分子和靶的方法
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
DK2740744T3
(da)
|
2007-01-09 |
2018-04-23 |
Biogen Ma Inc |
Sp35-antistoffer og anvendelser deraf
|
KR20090100461A
(ko)
|
2007-01-16 |
2009-09-23 |
아보트 러보러터리즈 |
건선의 치료방법
|
CL2008000188A1
(es)
|
2007-01-23 |
2008-07-18 |
Chugai Pharmaceutical Co Ltd |
Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
|
JP5507851B2
(ja)
|
2007-02-09 |
2014-05-28 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Gabaニューロン前駆細胞マーカー65b13
|
US7834154B2
(en)
|
2007-02-09 |
2010-11-16 |
Genentech, Inc. |
Anti-ROBO4 antibodies and uses therefor
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
US8114606B2
(en)
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
US8551484B2
(en)
*
|
2007-02-21 |
2013-10-08 |
University Of Massachusetts |
Human antibodies against hepatitis C virus (HCV) and uses thereof
|
CN101663407B
(zh)
|
2007-02-22 |
2017-08-08 |
健泰科生物技术公司 |
用于检测炎性肠病的方法
|
CN101951953A
(zh)
|
2007-02-27 |
2011-01-19 |
株式会社未来创药研究所 |
含抗grp78抗体作为有效成分的药物组合物
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
CN101652388B
(zh)
|
2007-03-13 |
2013-12-25 |
苏黎世大学 |
单克隆人肿瘤特异性抗体
|
EP2474556A3
(en)
|
2007-03-14 |
2012-10-17 |
Novartis AG |
APCDD1 inhibitors for treating, diagnosing or detecting cancer
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
CN101679507A
(zh)
|
2007-03-29 |
2010-03-24 |
艾博特公司 |
结晶抗人类il-12抗体
|
EP2703007A1
(en)
|
2007-03-30 |
2014-03-05 |
MedImmune, LLC |
Antibodies with decreased deamidation profiles
|
BRPI0809677A2
(pt)
|
2007-04-02 |
2014-10-07 |
Pfizer |
Anticorpos anti-ige
|
AU2008255027B2
(en)
|
2007-05-14 |
2013-10-03 |
Astrazeneca Ab |
Methods of reducing eosinophil levels
|
MX343167B
(es)
|
2007-05-21 |
2016-10-26 |
Genentech Inc * |
Metodos y composiciones para identificar y tratar lupus.
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
PT2336329E
(pt)
|
2007-06-01 |
2012-12-24 |
Omt Inc |
Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
|
CA3006428A1
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
MX2009013816A
(es)
|
2007-06-21 |
2010-02-24 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos.
|
PL2586788T3
(pl)
|
2007-07-09 |
2018-05-30 |
Genentech, Inc. |
Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
|
US8680247B2
(en)
|
2007-07-17 |
2014-03-25 |
Medarex, L.L.C. |
Monoclonal antibodies against glypican-3
|
EP3246045A1
(en)
|
2007-07-26 |
2017-11-22 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
BRPI0815578B8
(pt)
|
2007-08-20 |
2021-05-25 |
Oncotherapy Science Inc |
peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
|
EP2189471B1
(en)
|
2007-08-20 |
2017-10-04 |
Oncotherapy Science, Inc. |
Foxm1 peptide and medicinal agent comprising the same
|
HUE037265T2
(hu)
|
2007-08-21 |
2018-08-28 |
Amgen Inc |
Humán c-fms antigént kötõ proteinek
|
LT2195023T
(lt)
|
2007-08-29 |
2018-06-25 |
Sanofi |
Humanizuoti anti-cxcr5 antikūnai, jų dariniai ir jų panaudojimas
|
KR20100080519A
(ko)
|
2007-08-30 |
2010-07-08 |
큐어디엠 인코포레이티드 |
프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
|
WO2009033743A1
(en)
|
2007-09-13 |
2009-03-19 |
University Of Zurich Prorektorat Forschung |
Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP4368721A2
(en)
|
2007-09-26 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
JP4535406B2
(ja)
|
2007-09-28 |
2010-09-01 |
中外製薬株式会社 |
血漿中動態が改善されたグリピカン3抗体
|
BRPI0817482B8
(pt)
|
2007-10-02 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
KR101558009B1
(ko)
|
2007-10-15 |
2015-10-19 |
추가이 세이야쿠 가부시키가이샤 |
항체의 제조 방법
|
WO2009051220A1
(ja)
|
2007-10-19 |
2009-04-23 |
Immunas Pharma, Inc. |
Aβオリゴマーに特異的に結合する抗体およびその利用
|
US20120047586A9
(en)
|
2007-10-24 |
2012-02-23 |
Otsuka Chemical Co., Ltd |
Polypeptide having enhanced effector function
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
MX2010004814A
(es)
|
2007-11-05 |
2010-08-10 |
Medimmune Llc |
Metodos para tratar esclerodermia.
|
CN102172395A
(zh)
|
2007-11-07 |
2011-09-07 |
健泰科生物技术公司 |
用于治疗微生物病症的组合物和方法
|
JP5730576B2
(ja)
|
2007-11-07 |
2015-06-10 |
ジェネンテック, インコーポレイテッド |
抗cd40抗体による治療に対するb細胞リンパ腫の応答性を評価するための方法及び組成物
|
SG186000A1
(en)
|
2007-11-12 |
2012-12-28 |
U3 Pharma Gmbh |
Axl antibodies
|
CN104109208A
(zh)
|
2007-11-14 |
2014-10-22 |
中外制药株式会社 |
使用抗gpr49抗体的癌症的诊断和治疗
|
EP2853544A1
(en)
|
2007-11-15 |
2015-04-01 |
Chugai Seiyaku Kabushiki Kaisha |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
US8715941B2
(en)
|
2007-11-16 |
2014-05-06 |
Arca Biopharma, Inc. |
Antibodies to LRP6
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
BRPI0821110B8
(pt)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
|
RU2596397C2
(ru)
|
2007-12-05 |
2016-09-10 |
Чугаи Сейяку Кабусики Кайся |
Терапевтическое средство от зуда
|
WO2009079259A2
(en)
|
2007-12-06 |
2009-06-25 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
EP2241333A1
(en)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
WO2009086003A1
(en)
|
2007-12-20 |
2009-07-09 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
CN101965366B
(zh)
|
2007-12-26 |
2016-04-27 |
生物测试股份公司 |
靶向cd138的免疫缀合物及其应用
|
WO2009080829A1
(en)
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Agents targeting cd138 and uses thereof
|
AU2008339913B2
(en)
|
2007-12-26 |
2014-03-20 |
Biotest Ag |
Methods and agents for improving targeting of CD138 expressing tumor cells
|
US9011864B2
(en)
|
2007-12-26 |
2015-04-21 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
WO2009092011A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
CA2711826C
(en)
|
2008-01-25 |
2018-02-27 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
MX2010008578A
(es)
|
2008-02-08 |
2010-11-10 |
Medimmune Llc |
Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
|
HUE031944T2
(en)
|
2008-02-08 |
2017-08-28 |
Immunas Pharma Inc |
Antibodies capable of specific binding of amyloid β-oligomers and their use
|
JO2913B1
(en)
*
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
KR101304150B1
(ko)
|
2008-03-04 |
2013-09-05 |
라브리스 바이올로직스 인코포레이티드 |
만성 통증의 치료 방법
|
US8178092B2
(en)
|
2008-03-18 |
2012-05-15 |
Abbott Laboratories |
Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
|
US20110020368A1
(en)
|
2008-03-25 |
2011-01-27 |
Nancy Hynes |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
US20110123530A1
(en)
|
2008-03-31 |
2011-05-26 |
Arron Joseph R |
Compositions and methods for treating and diagnosing asthma
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
WO2009124109A1
(en)
|
2008-04-04 |
2009-10-08 |
The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services |
Human monoclonal antibodies specific for cd22
|
TWI564021B
(zh)
|
2008-04-11 |
2017-01-01 |
Chugai Pharmaceutical Co Ltd |
Repeated binding of antigen to antigen binding molecules
|
US8273351B2
(en)
|
2008-04-25 |
2012-09-25 |
Dyax Corp. |
Fc receptor binding proteins
|
EP2899209A1
(en)
|
2008-04-29 |
2015-07-29 |
Abbvie Inc. |
Dual Variable Domain Immunoglobulins and uses thereof
|
EP2816059A1
(en)
|
2008-05-01 |
2014-12-24 |
Amgen, Inc |
Anti-hepcidin antibodies and methods of use
|
WO2009135181A2
(en)
|
2008-05-02 |
2009-11-05 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
JP5890174B2
(ja)
|
2008-05-09 |
2016-03-22 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
終末糖化産物受容体(rage)に対する抗体及びその使用
|
EP2304439A4
(en)
|
2008-05-29 |
2012-07-04 |
Nuclea Biotechnologies Llc |
ANTI-phospho-AKT ANTIBODY
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
JP5723769B2
(ja)
|
2008-06-03 |
2015-05-27 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
BRPI0913406A2
(pt)
|
2008-06-03 |
2018-01-09 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e usos das mesmas
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
KR101665729B1
(ko)
|
2008-06-05 |
2016-10-12 |
국립연구개발법인 고쿠리츠간켄큐센터 |
신경침윤 억제제
|
AU2009269704B2
(en)
|
2008-06-16 |
2014-06-12 |
Patrys Limited |
LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same
|
EP2319869B1
(en)
|
2008-06-20 |
2016-08-17 |
National University Corporation Okayama University |
ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME
|
KR20110040886A
(ko)
|
2008-07-08 |
2011-04-20 |
아보트 러보러터리즈 |
프로스타글란딘 e2 결합 단백질 및 이의 용도
|
CA2729949A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
AU2009269099B2
(en)
|
2008-07-09 |
2016-03-10 |
Biogen Ma Inc. |
Compositions comprising antibodies to LINGO or fragments thereof
|
ES2442024T3
(es)
|
2008-07-15 |
2014-02-07 |
Academia Sinica |
Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
|
NZ591471A
(en)
|
2008-08-18 |
2012-08-31 |
Pfizer |
Antibodies to ccr2
|
US20120128684A1
(en)
|
2008-08-25 |
2012-05-24 |
Burnham Institute For Medical Research |
Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
|
ES2628108T3
(es)
|
2008-09-03 |
2017-08-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos multiespecíficos
|
KR101432474B1
(ko)
|
2008-09-07 |
2014-08-21 |
글라이코넥스 인코포레이티드 |
항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
|
JP2012504939A
(ja)
|
2008-09-23 |
2012-03-01 |
ワイス・エルエルシー |
架橋結合タンパク質による活性化シグナルの産生を予測するための方法
|
EP2346994B1
(en)
|
2008-09-30 |
2022-02-16 |
Ablexis, LLC |
Knock-in mice for the production of chimeric antibodies
|
EP2344632B1
(en)
|
2008-10-09 |
2022-12-28 |
Minerva Biotechnologies Corporation |
Method for inducing pluripotency in cells
|
EA032727B1
(ru)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Мутантный резистентный к протеолизу полипептид fgf21 и его применение
|
TWI572359B
(zh)
|
2008-10-14 |
2017-03-01 |
建南德克公司 |
免疫球蛋白變異體及其用途
|
US20120251502A1
(en)
|
2008-10-24 |
2012-10-04 |
The Government of the US as Represented by the Secretary of the Dept. of health |
Human Ebola Virus Species and Compositions and Methods Thereof
|
AU2009314311B2
(en)
|
2008-10-29 |
2013-01-10 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
AR073997A1
(es)
|
2008-10-29 |
2010-12-15 |
Wyeth Corp |
Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
US8642280B2
(en)
|
2008-11-07 |
2014-02-04 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
HRP20240240T1
(hr)
|
2008-12-09 |
2024-04-26 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
BRPI0923157B1
(pt)
|
2008-12-19 |
2021-12-28 |
University Of Zürich |
Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
|
JP5734201B2
(ja)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
JP5523346B2
(ja)
|
2008-12-22 |
2014-06-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Neph3を用いた膵臓前駆細胞の取得方法
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
WO2010075548A2
(en)
|
2008-12-23 |
2010-07-01 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
SG172427A1
(en)
|
2008-12-26 |
2011-07-28 |
Univ Tokyo |
Diagnosis and treatment of cancer using anti-lgr7 antibody
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
CA2749572A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
US20130122052A1
(en)
|
2009-01-20 |
2013-05-16 |
Homayoun H. Zadeh |
Antibody mediated osseous regeneration
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010091182A2
(en)
|
2009-02-04 |
2010-08-12 |
Molecular Innovations |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
|
US8309530B2
(en)
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
CA2744103C
(en)
|
2009-02-24 |
2018-01-02 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Methods for identifying immunobinders of cell-surface antigens
|
EP2810652A3
(en)
|
2009-03-05 |
2015-03-11 |
AbbVie Inc. |
IL-17 binding proteins
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
CA3018235C
(en)
|
2009-03-20 |
2021-01-12 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
CA2755640C
(en)
|
2009-03-20 |
2018-05-22 |
Genentech, Inc. |
Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
|
EP2411412B1
(en)
|
2009-03-24 |
2015-05-27 |
Teva Biopharmaceuticals USA, Inc. |
Humanized antibodies against light and uses thereof
|
EP3009145A1
(en)
|
2009-03-30 |
2016-04-20 |
Mount Sinai School of Medicine of New York University |
Influenza virus vaccines and uses thereof
|
MX347978B
(es)
|
2009-04-01 |
2017-05-22 |
Genentech Inc * |
Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina.
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
US8647623B2
(en)
|
2009-04-10 |
2014-02-11 |
Kyowa Hakko Kirin Co., Ltd |
Method for treatment of blood tumor using anti-TIM-3 antibody
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
AU2010236256C1
(en)
|
2009-04-16 |
2015-10-22 |
Abbvie Biotherapeutics Inc. |
Anti-TNF-alpha antibodies and their uses
|
ES2641612T3
(es)
|
2009-04-17 |
2017-11-10 |
Immunas Pharma, Inc. |
Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
|
US9617600B2
(en)
|
2009-04-18 |
2017-04-11 |
Genentech, Inc. |
Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
|
WO2010126066A1
(ja)
|
2009-04-27 |
2010-11-04 |
協和発酵キリン株式会社 |
血液腫瘍治療を目的とした抗IL-3Rα抗体
|
CN102753579A
(zh)
|
2009-05-01 |
2012-10-24 |
国立大学法人东京大学 |
抗钙粘着蛋白抗体
|
JP2012525847A
(ja)
|
2009-05-05 |
2012-10-25 |
アムジエン・インコーポレーテツド |
Fgf21変異体およびその使用
|
PE20160718A1
(es)
|
2009-05-05 |
2016-08-03 |
Amgen Inc |
Polipeptidos mutantes fgf21
|
US8673314B2
(en)
|
2009-05-26 |
2014-03-18 |
Mount Sinai School Of Medicine |
Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
|
EP2436397B1
(en)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition containing antagonist of egf family ligand as component
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
JP5785941B2
(ja)
|
2009-06-17 |
2015-09-30 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
抗vegf抗体とその使用
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
WO2011006001A1
(en)
|
2009-07-09 |
2011-01-13 |
Genentech, Inc. |
Animal model for the evaluation of adjuvant therapies of cancer
|
KR20120106935A
(ko)
|
2009-07-13 |
2012-09-27 |
제넨테크, 인크. |
암의 치료를 위한 진단 방법 및 조성물
|
US9217157B2
(en)
|
2009-07-27 |
2015-12-22 |
Icahn School Of Medicine At Mount Sinai |
Recombinant influenza viruses and uses thereof
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
CA2805505C
(en)
|
2009-07-30 |
2021-08-03 |
Mount Sinai School Of Medecine |
Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
|
KR20120089253A
(ko)
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
EP2460538B1
(en)
|
2009-07-31 |
2017-09-13 |
Shin Maeda |
Cancer metastasis inhibitor
|
EP2462451B1
(en)
|
2009-08-05 |
2016-02-17 |
Nexigen GmbH |
Human hcv-interacting proteins and methods of use
|
CN102574915B
(zh)
|
2009-08-06 |
2014-10-22 |
伊缪纳斯制药株式会社 |
特异性结合Aβ寡聚体的抗体及其用途
|
EP2462162B1
(en)
|
2009-08-06 |
2016-10-12 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to a beta oligomers and use thereof
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
PT2464725T
(pt)
|
2009-08-11 |
2020-05-21 |
Hoffmann La Roche |
Produção de proteínas em meios de cultura celular isentos de glutamina
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
AU2010282282A1
(en)
|
2009-08-14 |
2012-03-01 |
Genentech, Inc. |
Biological markers for monitoring patient response to VEGF antagonists
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
CA2771436A1
(en)
|
2009-08-17 |
2011-02-24 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
CN107441487B
(zh)
|
2009-08-28 |
2021-09-14 |
泰华制药国际有限公司 |
通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
|
EP2470568A2
(en)
|
2009-08-29 |
2012-07-04 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
RU2012112550A
(ru)
|
2009-09-01 |
2013-10-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
MX2012002766A
(es)
|
2009-09-03 |
2012-04-02 |
Genentech Inc |
Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
|
RU2012114094A
(ru)
|
2009-09-11 |
2013-10-20 |
Дженентек, Инк. |
Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
|
CN102630168A
(zh)
|
2009-09-14 |
2012-08-08 |
雅培制药有限公司 |
用于治疗银屑病的方法
|
JP5606537B2
(ja)
|
2009-09-17 |
2014-10-15 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
癌患者における診断使用のための方法及び組成物
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
KR101782180B1
(ko)
|
2009-09-30 |
2017-10-23 |
제넨테크, 인크. |
Notch3 길항제를 사용한 Notch1―길항제-내성 암(들)의 치료
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
LT2486141T
(lt)
|
2009-10-07 |
2018-05-25 |
Macrogenics, Inc. |
Fc regioną turintys polipeptidai, pasižymintys pagerinta efektorine funkcija dėl fukozilinimo laipsnio pasikeitimų, ir jų naudojimo būdai
|
EP3839068A3
(en)
|
2009-10-07 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Methods for treating, diagnosing, and monitoring lupus
|
CA2775959A1
(en)
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056606A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2011059762A1
(en)
|
2009-10-28 |
2011-05-19 |
Abbott Biotherapeutics Corp. |
Anti-egfr antibodies and their uses
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
WO2011057188A1
(en)
|
2009-11-06 |
2011-05-12 |
Idexx Laboratories, Inc. |
Canine anti-cd20 antibodies
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
GB0919751D0
(en)
|
2009-11-11 |
2009-12-30 |
King S College Hospital Nhs Fo |
Conjugate molecule
|
WO2011062997A2
(en)
|
2009-11-17 |
2011-05-26 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
WO2011063277A1
(en)
|
2009-11-20 |
2011-05-26 |
Amgen Inc. |
Anti-orai1 antigen binding proteins and uses thereof
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
EP2510001B1
(en)
|
2009-12-08 |
2015-12-02 |
AbbVie Deutschland GmbH & Co KG |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
ES2594893T3
(es)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
AU2010339770B2
(en)
|
2009-12-21 |
2015-02-12 |
Genentech, Inc. |
Antibody formulation
|
SG181905A1
(en)
|
2009-12-23 |
2012-07-30 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
WO2011092989A1
(ja)
|
2010-01-29 |
2011-08-04 |
東レ株式会社 |
ポリ乳酸系樹脂シート
|
CA2789310C
(en)
|
2010-02-10 |
2018-01-09 |
Fujifilm Ri Pharma Co., Ltd. |
Radioactive metal-labeled anti-cadherin antibody
|
WO2011103453A2
(en)
|
2010-02-18 |
2011-08-25 |
Mount Sinai School Of Medicine |
Vaccines for use in the prophylaxis and treatment of influenza virus disease
|
US8859736B2
(en)
|
2010-02-19 |
2014-10-14 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
SG10201501562VA
(en)
|
2010-03-02 |
2015-04-29 |
Abbvie Inc |
Therapeutic dll4 binding proteins
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
JP2013526849A
(ja)
|
2010-03-30 |
2013-06-27 |
モウント シナイ スクール オフ メディシネ |
インフルエンザウイルスワクチン及びその使用
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
KR102004106B1
(ko)
|
2010-03-31 |
2019-07-25 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
US9517264B2
(en)
|
2010-04-15 |
2016-12-13 |
Amgen Inc. |
Human FGF receptor and β-Klotho binding proteins
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
IL208820A0
(en)
|
2010-10-19 |
2011-01-31 |
Rachel Teitelbaum |
Biologic female contraceptives
|
CA2835489C
(en)
|
2010-05-10 |
2018-03-06 |
Chi-Huey Wong |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
TWI500427B
(zh)
|
2010-05-14 |
2015-09-21 |
Abbvie Inc |
Il-1結合蛋白
|
US20110293629A1
(en)
|
2010-05-14 |
2011-12-01 |
Bastid Jeremy |
Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011149051A1
(ja)
|
2010-05-28 |
2011-12-01 |
中外製薬株式会社 |
抗腫瘍t細胞応答増強剤
|
EP2578233B1
(en)
|
2010-05-28 |
2017-04-26 |
National Cancer Center |
Therapeutic agent for pancreatic cancer
|
ES2648885T3
(es)
|
2010-06-02 |
2018-01-08 |
Dana-Farber Cancer Institute, Inc. |
Anticuerpos monoclonales humanizados y métodos de uso
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011153346A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
EP2580239A1
(en)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
JP6029581B2
(ja)
|
2010-06-19 |
2016-11-24 |
メモリアル スローン−ケタリング キャンサー センター |
抗gd2抗体
|
WO2011161427A2
(en)
|
2010-06-25 |
2011-12-29 |
Aston University |
Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
NZ703035A
(en)
|
2010-07-09 |
2016-06-24 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
CA2804246A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
KR20130055647A
(ko)
|
2010-07-19 |
2013-05-28 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
WO2012018790A2
(en)
|
2010-08-03 |
2012-02-09 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
JP2013535692A
(ja)
|
2010-08-10 |
2013-09-12 |
アムジエン・インコーポレーテツド |
標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
WO2012024187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
SI3333188T1
(sl)
|
2010-08-19 |
2022-04-29 |
Zoetis Belgium S.A. |
Protitelesa proti NGF in njihova uporaba
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
EP2609431B1
(en)
|
2010-08-27 |
2017-05-10 |
University of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
MX351706B
(es)
|
2010-09-17 |
2017-10-25 |
Baxalta Inc |
Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro.
|
WO2012040518A2
(en)
|
2010-09-22 |
2012-03-29 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
CA2813738A1
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP2627672B1
(en)
|
2010-10-11 |
2018-08-01 |
Biogen Idec International Neuroscience GmbH |
Human anti-tau antibodies
|
US9272052B2
(en)
|
2010-10-22 |
2016-03-01 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
KR20140014077A
(ko)
|
2010-10-25 |
2014-02-05 |
리전츠 오브 더 유니버스티 오브 미네소타 |
교모세포종의 치료를 위한 치료 조성물
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
ES2931477T3
(es)
|
2010-10-29 |
2022-12-29 |
Perseus Proteomics Inc |
Anticuerpo anti-CDH3 que tiene alta capacidad de internalización
|
WO2012065937A1
(en)
|
2010-11-15 |
2012-05-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
MY166429A
(en)
|
2010-11-17 |
2018-06-26 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
EP2647706B1
(en)
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
CA2818781C
(en)
|
2010-12-17 |
2019-10-08 |
Neurimmune Holding Ag |
Human anti-sod1 antibodies
|
SG191312A1
(en)
|
2010-12-21 |
2013-07-31 |
Abbvie Inc |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
PL2654781T3
(pl)
|
2010-12-21 |
2018-09-28 |
Novartis Ag |
Przeciwciała anty-p-selektynowe i sposoby ich zastosowania i identyfikacji
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
WO2012092376A2
(en)
|
2010-12-31 |
2012-07-05 |
Short Jay M |
Comprehensive monoclonal antibody generation
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
JP5299440B2
(ja)
|
2011-01-13 |
2013-09-25 |
横河電機株式会社 |
経路設定装置、経路設定方法、管理装置、管理システム、及び記録媒体
|
WO2012099983A1
(en)
|
2011-01-18 |
2012-07-26 |
Amgen Inc. |
Nav1.7 knockout mice and uses thereof
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
EP2678026B1
(en)
|
2011-02-21 |
2016-05-18 |
The University of Zurich |
Ankyrin g for use in the treatment of neurodegenerative disorders
|
JP6032818B2
(ja)
|
2011-02-25 |
2016-11-30 |
中外製薬株式会社 |
FcγRIIb特異的Fc抗体
|
KR20140022815A
(ko)
|
2011-02-28 |
2014-02-25 |
제넨테크, 인크. |
B-세포 길항제에 대한 반응을 예측하기 위한 생물학적 마커 및 방법
|
WO2012118903A2
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
WO2012125775A1
(en)
|
2011-03-16 |
2012-09-20 |
Sanofi |
Uses of a dual v region antibody-like protein
|
EP2500073A1
(en)
|
2011-03-17 |
2012-09-19 |
ChromaCon AG |
Method for identification and purification of multi-specific polypeptides
|
WO2012128377A1
(ja)
|
2011-03-18 |
2012-09-27 |
国立大学法人鹿児島大学 |
膵臓癌の治療用及び診断用の組成物
|
WO2012129520A1
(en)
|
2011-03-24 |
2012-09-27 |
Texas Tech University System |
Tcr mimic antibodies as vascular targeting tools
|
DK2698431T3
(da)
|
2011-03-30 |
2020-11-30 |
Chugai Pharmaceutical Co Ltd |
Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
|
KR20140027211A
(ko)
|
2011-04-04 |
2014-03-06 |
유니버시티 오브 아이오와 리써치 파운데이션 |
백신 면역원성의 개선 방법
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
US8975029B2
(en)
|
2011-05-19 |
2015-03-10 |
The Regents Of The University Of Michigan |
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
|
WO2012162068A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
EP2530088A1
(en)
|
2011-05-30 |
2012-12-05 |
Klinikum rechts der Isar der Technischen Universität München |
Means and methods for diagnosing and treating multiple sclerosis
|
ES2748583T3
(es)
|
2011-06-02 |
2020-03-17 |
Dyax Corp |
Proteínas de unión al receptor Fc
|
SI2714735T1
(sl)
|
2011-06-03 |
2021-12-31 |
Xoma Technology Ltd. |
Protitelesa, specifična za TGF-beta
|
WO2012170071A1
(en)
|
2011-06-06 |
2012-12-13 |
Elan Pharmaceuticas, Inc |
Mcam antagonists and methods of treatment
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
RS57024B1
(sr)
|
2011-06-10 |
2018-05-31 |
Medimmune Ltd |
Anti-pseudomonas psl vezujući molekuli i njihova upotreba
|
AU2012271329A1
(en)
|
2011-06-17 |
2013-12-19 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using Clec-2
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
PT2723379T
(pt)
|
2011-06-23 |
2018-11-14 |
Univ Of Zuerich |
Moléculas de ligação anti-alfa-sinucleína
|
RU2641256C2
(ru)
|
2011-06-30 |
2018-01-16 |
Чугаи Сейяку Кабусики Кайся |
Гетеродимеризованный полипептид
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
CA2841970A1
(en)
|
2011-07-13 |
2013-01-17 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
MY170117A
(en)
|
2011-08-01 |
2019-07-05 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
WO2013017691A1
(en)
|
2011-08-04 |
2013-02-07 |
Medizinische Universität Innsbruck |
Cahgt1p inhibitors for use in the treatment of candidiasis
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
US9550835B2
(en)
|
2011-08-23 |
2017-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-DDR1 antibody having anti-tumor activity
|
WO2013034660A1
(en)
|
2011-09-09 |
2013-03-14 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
EA201490659A1
(ru)
|
2011-09-20 |
2014-11-28 |
Маунт Синай Скул Оф Медсин |
Вакцины против вируса гриппа и их применения
|
CA2849274C
(en)
|
2011-09-21 |
2018-12-04 |
Fujirebio Inc. |
Antibody against affinity complex
|
EP2758438A1
(en)
|
2011-09-23 |
2014-07-30 |
Amgen Research (Munich) GmbH |
Bispecific binding molecules for 5t4 and cd3
|
US10556949B2
(en)
|
2011-09-30 |
2020-02-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
PL2760471T3
(pl)
|
2011-09-30 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Peptydy terapeutyczne
|
BR122019023952B1
(pt)
|
2011-09-30 |
2022-09-20 |
Chugai Seiyaku Kabushiki Kaisha |
Biblioteca de anticorpos dependentes de concentração de íon
|
AU2012317418B2
(en)
|
2011-09-30 |
2017-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
EP2762493B1
(en)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
EP2764118A1
(en)
|
2011-10-05 |
2014-08-13 |
University of Bremen |
Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
EP2765192A4
(en)
|
2011-10-05 |
2015-04-15 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
|
CA2852244C
(en)
|
2011-10-17 |
2023-10-17 |
Minerva Biotechnologies Corporation |
Media for stem cell proliferation and induction
|
US10246509B2
(en)
*
|
2011-10-17 |
2019-04-02 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
CA2852758C
(en)
|
2011-10-21 |
2020-12-29 |
Augurex Life Sciences Corporation |
Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
|
IN2014CN03936A
(ko)
|
2011-10-24 |
2015-09-04 |
Abbvie Inc |
|
JP2014533659A
(ja)
|
2011-10-24 |
2014-12-15 |
アッヴィ・インコーポレイテッド |
スクレロスチンに対するイムノバインダー
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
GB2496375A
(en)
*
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
BR112014010257A2
(pt)
|
2011-10-31 |
2017-04-18 |
Chugai Pharmaceutical Co Ltd |
molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
|
LT3091029T
(lt)
|
2011-10-31 |
2023-02-27 |
F. Hoffmann-La Roche Ag |
Anti-il13 antikūno kompozicijos
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
AU2012332587B2
(en)
|
2011-11-01 |
2017-02-23 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
AU2012335247A1
(en)
|
2011-11-08 |
2014-05-29 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-M-CSF antibodies
|
US20140323549A1
(en)
|
2011-11-08 |
2014-10-30 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
WO2013068432A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
EP2776022A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
BR112014013081A2
(pt)
|
2011-11-30 |
2020-10-20 |
Chugai Seiyaku Kabushiki Kaisha |
veículo contendo fármaco em célula para formação de um complexo imune
|
US10117932B2
(en)
|
2011-12-08 |
2018-11-06 |
Biotest Ag |
Uses of immunoconjugates targeting CD138
|
AU2012347540A1
(en)
|
2011-12-08 |
2014-06-26 |
Amgen Inc. |
Agonistic human LCAT antigen binding proteins and their use in therapy
|
EP2602621A1
(en)
|
2011-12-08 |
2013-06-12 |
Julius-Maximilians-Universität Würzburg |
LASP-1, a novel urinary marker for transitional cell carcinoma detection
|
WO2013090633A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CA2855840C
(en)
|
2011-12-14 |
2023-08-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
US20150030602A1
(en)
|
2011-12-23 |
2015-01-29 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
EP2797952B1
(en)
|
2011-12-28 |
2019-02-27 |
ImmunoQure AG |
Method of providing monoclonal auto-antibodies with desired specificity
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
BR112014015851A2
(pt)
|
2011-12-30 |
2019-09-24 |
Abbvie Inc |
proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
EP2802601B1
(en)
|
2012-01-09 |
2019-11-13 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
EP2802346B1
(en)
|
2012-01-13 |
2018-09-12 |
F.Hoffmann-La Roche Ag |
Biological markers for identifying patients for treatment with vegf antagonists
|
CN104471064B
(zh)
|
2012-01-20 |
2018-11-02 |
中华人民共和国香港特别行政区政府 |
副粘病毒及其用途
|
PE20142168A1
(es)
|
2012-01-27 |
2015-01-17 |
AbbVie Deutschland GmbH and Co KG |
Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
|
AU2013215332A1
(en)
|
2012-01-31 |
2014-09-04 |
Genentech, Inc. |
Anti-Ig-E M1' antibodies and methods using same
|
US20150210763A1
(en)
|
2012-02-09 |
2015-07-30 |
Chugai Seiyaku Kabushiki Kaisha |
MODIFIED Fc REGION OF ANTIBODY
|
WO2013119990A2
(en)
|
2012-02-10 |
2013-08-15 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
JP6400480B2
(ja)
|
2012-02-15 |
2018-10-03 |
ノヴォ ノルディスク アー/エス |
ペプチドグリカン認識タンパク質1に結合する抗体
|
TWI605061B
(zh)
|
2012-02-15 |
2017-11-11 |
諾佛 儂迪克股份有限公司 |
會結合及阻斷表現在骨髓細胞上觸發受體-1(trem-1)之抗體
|
WO2013126813A1
(en)
|
2012-02-22 |
2013-08-29 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
SG11201405137QA
(en)
|
2012-02-24 |
2014-12-30 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
|
EP2820047B1
(en)
|
2012-03-01 |
2018-04-25 |
Amgen Research (Munich) GmbH |
Long life polypeptide binding molecules
|
EP2820044A1
(en)
*
|
2012-03-02 |
2015-01-07 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to clostridium difficile toxins
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
KR102197524B1
(ko)
|
2012-03-27 |
2020-12-31 |
제넨테크, 인크. |
특발성 폐 섬유증의 예후, 진단 및 치료 방법
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
JP6280031B2
(ja)
|
2012-03-29 |
2018-02-14 |
中外製薬株式会社 |
抗lamp5抗体およびその利用
|
EP2831117B1
(en)
|
2012-03-29 |
2017-11-01 |
NovImmune SA |
Anti-tlr4 antibodies and uses thereof
|
SG10201509939PA
(en)
|
2012-03-30 |
2016-01-28 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
WO2013150623A1
(ja)
|
2012-04-04 |
2013-10-10 |
株式会社ペルセウスプロテオミクス |
抗cdh3(p-カドヘリン)抗体の薬剤コンジュゲート
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
TIKI INHIBITORS
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
EP3929208A1
(en)
|
2012-04-27 |
2021-12-29 |
Amgen Inc. |
Human cd30 ligand antigen binding proteins
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
EP2844291B1
(en)
|
2012-05-03 |
2019-02-13 |
Fibrogen, Inc. |
Methods for treating idiopathic pulmonary fibrosis
|
WO2013166500A1
(en)
|
2012-05-04 |
2013-11-07 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
EP2849787A4
(en)
|
2012-05-14 |
2016-06-15 |
Biogen Ma Inc |
LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISORDERS INVOLVING ENGINE NEURONS
|
KR20220051197A
(ko)
|
2012-05-17 |
2022-04-26 |
익스텐드 바이오사이언시즈, 인크. |
개선된 약물 전달용 캐리어
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
TWI617578B
(zh)
|
2012-05-30 |
2018-03-11 |
Chugai Pharmaceutical Co Ltd |
標的組織專一的抗原結合分子
|
JPWO2013180201A1
(ja)
|
2012-05-30 |
2016-01-21 |
中外製薬株式会社 |
会合化した抗原を消失させる抗原結合分子
|
JP6312659B2
(ja)
|
2012-05-31 |
2018-04-18 |
ジェネンテック, インコーポレイテッド |
Pd−1系結合アンタゴニスト及びvegfアンタゴニストを用いた癌の治療方法
|
WO2013184871A1
(en)
|
2012-06-06 |
2013-12-12 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
SG11201408042YA
(en)
|
2012-06-15 |
2015-01-29 |
Pfizer |
Improved antagonist antibodies against gdf-8 and uses therefor
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(en)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
EP2869818A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
WO2014011988A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
EP2888238A4
(en)
|
2012-08-21 |
2016-01-27 |
Academia Sinica |
BENZOCYCLO-OCTYNE COMPOUNDS AND USES THEREOF
|
US11236168B2
(en)
|
2012-08-24 |
2022-02-01 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse FcγammaRII-specific Fc antibody
|
BR112015001955A2
(pt)
|
2012-08-24 |
2017-11-07 |
Chugai Pharmaceutical Co Ltd |
variante de região fc específica de fcgamariib
|
BR112015004229B1
(pt)
|
2012-08-31 |
2023-02-07 |
Immunogen, Inc |
Anticorpos ou fragmentos de ligação ao antígeno do mesmo que se liga especificamente à proteína folr1, kit de imunoensaio, método de detecção in vitro de proteína folr1, uso de um agente ativo, e método para monitoramento da eficácia terapêutica
|
EP2897631A4
(en)
|
2012-08-31 |
2016-10-05 |
Univ Virginia Patent Found |
TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSIS
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
SG11201504249XA
(en)
|
2012-09-02 |
2015-07-30 |
Abbvie Inc |
Methods to control protein heterogeneity
|
CA2883673A1
(en)
|
2012-09-05 |
2014-03-13 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
EP2898327A1
(en)
|
2012-09-19 |
2015-07-29 |
Dana-Farber Cancer Institute, Inc. |
Dynamic bh3 profiling
|
EP2711016A1
(en)
|
2012-09-21 |
2014-03-26 |
Covagen AG |
Novel IL-17A binding molecules and medical uses thereof
|
CN107501413A
(zh)
|
2012-09-27 |
2017-12-22 |
中外制药株式会社 |
Fgfr3融合基因和以其作为标靶的药物
|
TWI609083B
(zh)
|
2012-09-28 |
2017-12-21 |
Chugai Pharmaceutical Co Ltd |
Blood coagulation reaction assessment method
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
NO2760138T3
(ko)
|
2012-10-01 |
2018-08-04 |
|
|
KR101947702B1
(ko)
|
2012-10-04 |
2019-02-14 |
다나-파버 캔서 인스티튜트 인크. |
인간 단클론 항-pd-l1 항체 및 사용 방법
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
JP6348115B2
(ja)
|
2012-10-26 |
2018-06-27 |
ザ ユニバーシティー オブ クイーンズランド |
がん療法のためのエンドサイトーシス阻害剤および抗体の使用
|
TW202210507A
(zh)
|
2012-11-01 |
2022-03-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
US9593165B2
(en)
|
2012-11-08 |
2017-03-14 |
University Of Miyazaki |
Antibody capable of specifically recognizing transferrin receptor
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
EP3725807A1
(en)
|
2012-12-03 |
2020-10-21 |
NovImmune SA |
Anti-cd47 antibodies and methods of use thereof
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
LT2928923T
(lt)
|
2012-12-10 |
2020-02-25 |
Biogen Ma Inc. |
Anti-kraujo dendritinių ląstelių antigeno 2 antikūnai ir jų panaudojimas
|
EP3756687A3
(en)
|
2012-12-13 |
2021-03-24 |
University Of Virginia Patent Foundation |
Target peptides for ovarian cancer therapy and diagnostics
|
NZ627796A
(en)
|
2012-12-18 |
2017-07-28 |
Icahn School Med Mount Sinai |
Influenza virus vaccines and uses thereof
|
RU2015129551A
(ru)
|
2012-12-19 |
2017-01-25 |
Эмплиммьюн, Инк. |
Антитела к в7-н4 человека и их применение
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
CA2896066C
(en)
|
2012-12-21 |
2022-07-12 |
Biogen Ma Inc. |
Human anti-tau antibodies
|
KR102249779B1
(ko)
|
2012-12-27 |
2021-05-07 |
추가이 세이야쿠 가부시키가이샤 |
헤테로이량화 폴리펩티드
|
WO2014102399A1
(en)
|
2012-12-31 |
2014-07-03 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
MX369175B
(es)
|
2013-02-25 |
2019-10-30 |
Genentech Inc |
Métodos para detectar mutantes de akt resistentes a fármacos.
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
MY185551A
(en)
|
2013-03-13 |
2021-05-19 |
Genentech Inc |
Antibody formulations
|
PL2968466T3
(pl)
|
2013-03-13 |
2018-11-30 |
F.Hoffmann-La Roche Ag |
Preparaty o zmniejszonym utlenianiu
|
MX370416B
(es)
|
2013-03-13 |
2019-12-10 |
Genentech Inc |
Formulaciones con oxidacion reducida.
|
EP2968555B1
(en)
|
2013-03-13 |
2020-06-17 |
Sanofi |
Compositions comprising anti-cd38 antibodies and carfilzomib
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
AU2014244444A1
(en)
|
2013-03-14 |
2015-09-24 |
Amgen Inc. |
CHRDL-1 antigen binding proteins and methods of treatment
|
CN105452292A
(zh)
|
2013-03-14 |
2016-03-30 |
帕卡什·吉尔 |
使用结合细胞表面grp78的抗体进行癌症治疗
|
CA2906417C
(en)
|
2013-03-14 |
2022-06-21 |
Robert Ziemann |
Hcv core lipid binding domain monoclonal antibodies
|
WO2014159960A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
CN105228649B
(zh)
|
2013-03-14 |
2019-01-18 |
雅培制药有限公司 |
Hcv抗原-抗体组合测定和方法以及用在其中的组合物
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
WO2014159242A1
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Notch 3 mutants and uses thereof
|
WO2014143342A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
|
JP2016513478A
(ja)
|
2013-03-15 |
2016-05-16 |
ジェネンテック, インコーポレイテッド |
細胞培養培地及び抗体を産生する方法
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
CA2904448A1
(en)
|
2013-03-15 |
2014-09-18 |
Tariq Ghayur |
Dual specific binding proteins directed against il-1.beta. and/or il-17
|
EP2970489A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25 antibodies and their uses
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
ES2779398T3
(es)
|
2013-03-15 |
2020-08-17 |
Dana-Farber Cancer Institute Inc |
Péptidos terapéuticos
|
EA201591806A1
(ru)
|
2013-03-15 |
2016-01-29 |
Байоджен Ма Инк. |
Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
BR112015023084A2
(pt)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
|
CN105705165B
(zh)
|
2013-03-15 |
2020-04-24 |
纪念斯隆-凯特琳癌症中心 |
高亲和力抗gd2抗体
|
EP3683237A1
(en)
|
2013-03-15 |
2020-07-22 |
Amgen Inc. |
Human pac1 antibodies
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
MX368665B
(es)
|
2013-03-15 |
2019-10-10 |
Abbvie Biotherapeutics Inc |
Variantes de fc.
|
US9822166B2
(en)
|
2013-03-15 |
2017-11-21 |
Dana-Farber Cancer Institute, Inc. |
Flavivirus neutralizing antibodies and methods of use thereof
|
AU2014233393B2
(en)
|
2013-03-15 |
2020-05-28 |
Genentech, Inc. |
Cell culture compositions with antioxidants and methods for polypeptide production
|
MX2015014017A
(es)
|
2013-04-02 |
2016-02-10 |
Chugai Pharmaceutical Co Ltd |
Variante de la region fc.
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
US20160053023A1
(en)
|
2013-04-09 |
2016-02-25 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗il-4/抗il-13之雙特異性抗體調配物
|
DK2981822T3
(da)
|
2013-05-06 |
2020-12-07 |
Scholar Rock Inc |
Sammensætninger og fremgangsmåder til vækstfaktormodulation
|
CN104140974B
(zh)
|
2013-05-08 |
2017-09-29 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
US9989540B2
(en)
|
2013-05-10 |
2018-06-05 |
The Regents Of The University Of California |
Diagnostic and monitoring system for Huntington's disease
|
CA2912526C
(en)
|
2013-05-16 |
2021-09-14 |
Kyoto University |
Method for determining prognosis of cancer
|
AU2014268298B2
(en)
|
2013-05-24 |
2019-01-17 |
Medlmmune, Llc |
Anti-B7-H5 antibodies and their uses
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
US10781259B2
(en)
|
2013-06-06 |
2020-09-22 |
Magenta Therapeutics, Inc. |
Modified antibodies and related compounds, compositions, and methods of use
|
ES2753419T3
(es)
|
2013-06-07 |
2020-04-08 |
Univ Duke |
Inhibidores del factor H del complemento
|
JP6442404B2
(ja)
|
2013-06-11 |
2018-12-19 |
国立研究開発法人国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
US9499628B2
(en)
|
2013-06-14 |
2016-11-22 |
Children's Hospital Medical Center |
Method of boosting the immune response in neonates
|
WO2014208482A1
(ja)
|
2013-06-24 |
2014-12-31 |
中外製薬株式会社 |
ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
EP4056591A1
(en)
|
2013-07-03 |
2022-09-14 |
ImmunoQure AG |
Human anti-ifn-alpha antibodies
|
SG10201710758PA
(en)
|
2013-07-09 |
2018-02-27 |
Annexon Inc |
Anti-complement factor c1q antibodies and uses thereof
|
US9873740B2
(en)
|
2013-07-16 |
2018-01-23 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
WO2015019286A1
(en)
|
2013-08-07 |
2015-02-12 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
US9879091B2
(en)
|
2013-08-07 |
2018-01-30 |
Astute Medical, Inc. |
Assays for TIMP2 having improved performance in biological samples
|
DK3036320T4
(da)
|
2013-08-19 |
2024-05-06 |
Biogen Ma Inc |
Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカAcademia Sinica |
改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
|
EP3047276B1
(en)
|
2013-09-19 |
2023-06-14 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
EP3047857A4
(en)
|
2013-09-20 |
2017-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
KR102331663B1
(ko)
|
2013-09-27 |
2021-11-25 |
제넨테크, 인크. |
항-pdl1 항체 제제
|
EP3050896B1
(en)
|
2013-09-27 |
2021-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
AU2014331909B2
(en)
|
2013-10-10 |
2020-03-12 |
Beth Israel Deaconess Medical Center, Inc. |
TM4SF1 binding proteins and methods of using same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
CA3120508A1
(en)
|
2013-10-28 |
2015-05-07 |
Dots Technology Corp. |
Allergen detection
|
SG11201603088RA
(en)
|
2013-10-31 |
2016-05-30 |
Sanofi Sa |
Specific anti-cd38 antibodies for treating human cancers
|
MX2016005834A
(es)
|
2013-11-06 |
2016-11-17 |
Astute Medical Inc |
Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.
|
CN105940107B
(zh)
|
2013-11-11 |
2021-06-15 |
中外制药株式会社 |
含有改变了抗体可变区的抗原结合分子
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
WO2015083764A1
(ja)
|
2013-12-04 |
2015-06-11 |
中外製薬株式会社 |
化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
|
AU2014360273A1
(en)
|
2013-12-06 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
CN106459187A
(zh)
|
2013-12-09 |
2017-02-22 |
纽约大学 |
用于抗葡萄球菌剂的吞噬细胞递送的组合物和方法
|
EP3080160B1
(en)
|
2013-12-13 |
2022-07-06 |
Rijksuniversiteit Groningen |
Antibodies against staphylococcus aureus and uses thereof
|
ES2763429T5
(es)
|
2013-12-17 |
2023-06-21 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
|
SG11201604979WA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
CA2931113C
(en)
|
2013-12-20 |
2023-07-11 |
Genentech, Inc. |
Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
|
WO2015095809A1
(en)
|
2013-12-20 |
2015-06-25 |
Biogen Idec Ma Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
EP3581179A1
(en)
|
2013-12-27 |
2019-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Fgfr gatekeeper mutant gene and drug targeting same
|
AU2014370873B2
(en)
|
2013-12-27 |
2020-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying antibody having low isoelectric point
|
EP2893939A1
(en)
|
2014-01-10 |
2015-07-15 |
Netris Pharma |
Anti-netrin-1 antibody
|
CN104774264B
(zh)
|
2014-01-15 |
2018-09-14 |
上海易乐生物技术有限公司 |
抗人proBDNF单克隆抗体及其在疼痛中的作用
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
EP3105252B1
(en)
|
2014-02-12 |
2019-07-24 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
CA2939006A1
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
US20170174751A1
(en)
|
2014-03-19 |
2017-06-22 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
KR102274964B1
(ko)
|
2014-03-21 |
2021-07-09 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
MX2016012288A
(es)
|
2014-03-25 |
2017-01-23 |
Genentech Inc |
Metodos para preparar un poloxamero para usar en medio de cultivo celular.
|
TWI797430B
(zh)
|
2014-03-27 |
2023-04-01 |
中央研究院 |
反應性標記化合物及其用途
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
BR112016022620A2
(pt)
|
2014-03-31 |
2017-10-10 |
Debiopharm Int Sa |
cdna que codifica um polipeptídeo de fusão, vetor, célula procariotica ou eucariotica, sequência polinucleotídica, polipeptídeo de fusão, anticorpo ou fragmento de ligação, par de primers, sonda oligonucleotídica, oligonucleotídeo, sirna dirigido a um rna mensageiro, inibidor da atividade quinase fgfr, método de terapia e método para identificar um composto
|
KR102352573B1
(ko)
|
2014-04-04 |
2022-01-18 |
바이오노믹스 인코포레이티드 |
Lgr5에 결합하는 인간화된 항체들
|
WO2015164865A1
(en)
|
2014-04-25 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
|
EP3148567A4
(en)
|
2014-04-25 |
2018-01-10 |
The Brigham and Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
US10345298B2
(en)
|
2014-04-30 |
2019-07-09 |
Klinikum Rechts Der Isar Der Technischen Universität München |
Diagnosis of multiple sclerosis
|
GB2541599B
(en)
|
2014-05-14 |
2020-05-20 |
Carsgen Therapeutics Ltd |
Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein
|
JP6832709B2
(ja)
|
2014-05-16 |
2021-02-24 |
メディミューン,エルエルシー |
新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
|
CA2949237C
(en)
|
2014-05-16 |
2022-08-23 |
Amgen Inc. |
Assay for detecting th1 and th2 cell populations
|
EP3145953A1
(en)
|
2014-05-21 |
2017-03-29 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer with anti bip or anti mica antibodies
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
TWI679020B
(zh)
|
2014-05-27 |
2019-12-11 |
中央研究院 |
抗her2醣抗體及其用途
|
CN107074945B
(zh)
|
2014-05-27 |
2021-08-24 |
中央研究院 |
增进抗体功效的通用糖型的组合物及方法
|
US10155818B2
(en)
|
2014-05-28 |
2018-12-18 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
EP3157535A1
(en)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
WO2016001830A1
(en)
|
2014-07-01 |
2016-01-07 |
Friedrich Miescher Institute For Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
SG11201700097WA
(en)
|
2014-07-09 |
2017-02-27 |
Genentech Inc |
Ph adjustment to improve thaw recovery of cell banks
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
EP3169361B1
(en)
|
2014-07-15 |
2019-06-19 |
F.Hoffmann-La Roche Ag |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
CN112979828A
(zh)
|
2014-07-17 |
2021-06-18 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
KR102641268B1
(ko)
|
2014-07-17 |
2024-02-27 |
노보 노르디스크 에이/에스 |
점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
MX2017001403A
(es)
|
2014-07-31 |
2017-07-07 |
Amgen Res (Munich) Gmbh |
Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
|
TW201609812A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
JP6669749B2
(ja)
|
2014-08-08 |
2020-03-18 |
アレクトル エルエルシー |
抗trem2抗体及びその使用方法
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
EP4056993A1
(en)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring viscosity of protein solution
|
EP3183002B1
(en)
|
2014-08-21 |
2021-03-03 |
Walter Reed Army Institute of Research |
Monoclonal antibodies for treatment of microbial infections
|
KR20240011258A
(ko)
|
2014-09-02 |
2024-01-25 |
이뮤노젠 아이엔씨 |
항체 약물 컨쥬게이트 조성물의 제형화 방법
|
US9879042B2
(en)
|
2014-09-08 |
2018-01-30 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
AR101875A1
(es)
|
2014-09-15 |
2017-01-18 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
|
WO2016044588A1
(en)
|
2014-09-19 |
2016-03-24 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
EP3201228A2
(en)
|
2014-09-30 |
2017-08-09 |
Neurimmune Holding AG |
Human-derived anti-dipeptide repeats (dprs) antibody
|
JP2017531427A
(ja)
|
2014-10-03 |
2017-10-26 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
グルココルチコイド誘導腫瘍壊死因子受容体(gitr)抗体およびその使用法
|
CN107250160B
(zh)
|
2014-10-06 |
2022-01-11 |
达纳-法伯癌症研究所公司 |
人源化cc趋化因子受体4 (ccr4)抗体及其使用方法
|
EP3722433B1
(en)
|
2014-10-15 |
2023-07-26 |
Amgen Inc. |
Promoter and regulatory elements for improved expression of heterologous genes in host cells
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
WO2016065042A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
JP6884697B2
(ja)
|
2014-10-31 |
2021-06-09 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
T細胞を刺激および拡大する組成物および方法
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
US10011657B2
(en)
|
2014-10-31 |
2018-07-03 |
Abbvie Biotherapeutics Inc. |
Anti-CS1 antibodies and antibody drug conjugates
|
KR20240075936A
(ko)
|
2014-10-31 |
2024-05-29 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Cart 세포에서 유전자 발현의 변경 및 그의 용도
|
WO2016073794A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
KR102626877B1
(ko)
|
2014-11-05 |
2024-01-19 |
애넥슨, 인코포레이티드 |
인간화 항-보체 인자 c1q 항체 및 이의 용도
|
MX2017005930A
(es)
|
2014-11-05 |
2017-06-30 |
Genentech Inc |
Metodo de produccion de proteinas de cadena doble en bacterias.
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
FI3218005T3
(fi)
|
2014-11-12 |
2023-03-31 |
Seagen Inc |
Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
|
SG11201703605QA
(en)
|
2014-11-17 |
2017-06-29 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3221445B1
(en)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Compositions and methods related to hematologic recovery
|
WO2016081835A2
(en)
|
2014-11-21 |
2016-05-26 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
US20160158360A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
CA2970155A1
(en)
|
2014-12-09 |
2016-06-16 |
Abbvie Inc. |
Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
|
WO2016094505A1
(en)
|
2014-12-09 |
2016-06-16 |
Abbvie Inc. |
Antibody drug conjugates with cell permeable bcl-xl inhibitors
|
KR20170087500A
(ko)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
WO2016097420A1
(en)
|
2014-12-19 |
2016-06-23 |
Universite De Nantes |
Anti il-34 antibodies
|
CA2972048C
(en)
|
2014-12-22 |
2023-03-07 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
WO2016112270A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
SG10201906471PA
(en)
|
2015-01-14 |
2019-09-27 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016118937A1
(en)
|
2015-01-23 |
2016-07-28 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
EP3789766A1
(en)
|
2015-01-24 |
2021-03-10 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
KR102630294B1
(ko)
|
2015-01-24 |
2024-01-26 |
아카데미아 시니카 |
암 마커 및 이를 사용하는 방법
|
CN107407677B
(zh)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
多发性硬化的基因表达标志和治疗
|
CN107614521B
(zh)
|
2015-01-30 |
2022-02-08 |
台湾地区“中央研究院” |
增进抗体功效的通用糖型组合物及方法
|
CA2975147A1
(en)
|
2015-01-31 |
2016-08-04 |
Yangbing Zhao |
Compositions and methods for t cell delivery of therapeutic molecules
|
WO2016126972A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3253778A1
(en)
|
2015-02-05 |
2017-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
CA2976074A1
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
JP6885869B2
(ja)
|
2015-02-26 |
2021-06-16 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
がんを治療するためのpd−1/pd−l1阻害剤
|
AU2016224409B2
(en)
|
2015-02-27 |
2021-01-28 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating IL-6-related diseases
|
CN108064169B
(zh)
|
2015-03-03 |
2022-02-11 |
科马布有限公司 |
抗体、用途和方法
|
WO2016141111A1
(en)
|
2015-03-03 |
2016-09-09 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
SG11201706659WA
(en)
|
2015-03-06 |
2017-09-28 |
Csl Behring Recombinant Facility Ag |
Modified von willebrand factor having improved half-life
|
EP3271387B1
(en)
|
2015-03-16 |
2023-12-06 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Trispecific binding molecules for treating hbv infection and associated conditions
|
WO2016149368A1
(en)
|
2015-03-17 |
2016-09-22 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
WO2016149621A1
(en)
|
2015-03-18 |
2016-09-22 |
The Johns Hopkins University |
Novel monoclonal antibody inhibitors targeting potassium channel kcnk9
|
EP3274468B1
(en)
|
2015-03-25 |
2019-02-20 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
|
US20180074077A1
(en)
|
2015-03-25 |
2018-03-15 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
ES2820768T3
(es)
|
2015-04-03 |
2021-04-22 |
Xoma Technology Ltd |
Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
|
US10849992B1
(en)
|
2015-04-07 |
2020-12-01 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
RS62546B1
(sr)
|
2015-04-07 |
2021-12-31 |
Alector Llc |
Antitela protiv sortilina i postupci za njihovu upotrebu
|
WO2016164835A1
(en)
|
2015-04-08 |
2016-10-13 |
Dana-Farber Cancer Institute, Inc. |
Humanized influenza monoclonal antibodies and methods of use thereof
|
AU2016248817A1
(en)
|
2015-04-17 |
2017-08-17 |
F. Hoffmann-La Roche Ag |
Combination therapy with coagulation factors and multispecific antibodies
|
JP6907124B2
(ja)
|
2015-04-17 |
2021-07-21 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
Cdh3及びcd3に対する二重特異性抗体構築物
|
BR112017022666A8
(pt)
|
2015-04-20 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Preparando resposta à alvocidib por perfilamento mitocondrial
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
JP6814745B2
(ja)
|
2015-04-27 |
2021-01-20 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法
|
EP3288977B1
(en)
|
2015-05-01 |
2021-11-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of mediating cytokine expression with anti ccr4 antibodies
|
KR20180015650A
(ko)
|
2015-05-07 |
2018-02-13 |
아게누스 인코포레이티드 |
항-ox40 항체 및 이의 사용 방법
|
US20160346387A1
(en)
|
2015-05-11 |
2016-12-01 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
DK3447075T3
(da)
|
2015-05-15 |
2023-11-13 |
Massachusetts Gen Hospital |
Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
|
CN111349118B
(zh)
|
2015-05-18 |
2023-08-22 |
住友制药肿瘤公司 |
具有增加的生物利用度的阿伏西地前药
|
WO2016191397A1
(en)
|
2015-05-22 |
2016-12-01 |
Td2 Inc. |
Benzamide and active compound compositions and methods of use
|
AU2016271591A1
(en)
|
2015-05-29 |
2017-12-21 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
PE20180193A1
(es)
|
2015-05-29 |
2018-01-26 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos
|
WO2016191811A1
(en)
|
2015-06-03 |
2016-12-08 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
EP3307771A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
KR20180018762A
(ko)
|
2015-06-16 |
2018-02-21 |
메르크 파텐트 게엠베하 |
Pd-l1 길항제 조합 치료
|
EP3310815A1
(en)
|
2015-06-17 |
2018-04-25 |
F. Hoffmann-La Roche AG |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
BR112017027736A2
(pt)
|
2015-06-29 |
2018-10-09 |
Genentech Inc |
anticorpo anti-cd20 tipo ii para uso no transplante de órgãos
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
MX2018001289A
(es)
|
2015-08-03 |
2018-04-30 |
Tolero Pharmaceuticals Inc |
Terapias de combinacion para el tratamiento del cancer.
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
WO2017024285A2
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
CA2995838A1
(en)
|
2015-08-19 |
2017-02-23 |
Rutgers, The State University Of New Jersey |
Novel methods of generating antibodies
|
CN117491623A
(zh)
|
2015-08-20 |
2024-02-02 |
豪夫迈·罗氏有限公司 |
使用聚乙二醇化分析物特异性结合剂的基于颗粒的免疫测定法
|
CN108137702B
(zh)
|
2015-08-28 |
2023-01-06 |
艾利妥 |
抗siglec-7抗体及其使用方法
|
BR112018003186A2
(pt)
|
2015-09-01 |
2018-09-25 |
Agenus Inc. |
anticorpos anti-pd-1 e seus métodos de uso
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
グリカンアレイおよび使用の方法
|
WO2017049004A1
(en)
|
2015-09-15 |
2017-03-23 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
TW202342532A
(zh)
|
2015-09-18 |
2023-11-01 |
日商中外製藥股份有限公司 |
Il-8結合抗體及其用途
|
US10017572B2
(en)
|
2015-09-25 |
2018-07-10 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
CA3000386A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
CA3000697A1
(en)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Treatment of bile acid disorders
|
KR20180068999A
(ko)
|
2015-10-06 |
2018-06-22 |
알렉터 엘엘씨 |
항-trem2 항체 및 그의 사용방법
|
EP3368566A1
(en)
|
2015-10-28 |
2018-09-05 |
Friedrich Miescher Institute for Biomedical Research |
Tenascin-w and biliary tract cancers
|
US10800844B2
(en)
|
2015-10-29 |
2020-10-13 |
Alector Llc |
Anti-Siglec-9 antibodies and methods of use thereof
|
TW201720459A
(zh)
|
2015-11-02 |
2017-06-16 |
妮翠斯製藥公司 |
Ntn1中和劑與抑制後生控制之藥物之組合治療
|
WO2017076492A1
(en)
|
2015-11-03 |
2017-05-11 |
Merck Patent Gmbh |
Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
|
IL258768B2
(en)
|
2015-11-12 |
2023-11-01 |
Siamab Therapeutics Inc |
Compounds interacting with glycans and methods of use
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
JP2019501139A
(ja)
|
2015-11-25 |
2019-01-17 |
イミュノジェン・インコーポレーテッド |
医薬製剤及びその使用
|
WO2017095805A1
(en)
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
EP3383910A1
(en)
|
2015-11-30 |
2018-10-10 |
AbbVie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
KR20180100122A
(ko)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
AU2016365318B2
(en)
|
2015-12-02 |
2024-04-18 |
Board Of Regents, The University Of Texas System |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
WO2017106578A1
(en)
|
2015-12-15 |
2017-06-22 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
EA201891323A1
(ru)
|
2015-12-23 |
2019-02-28 |
Амген Инк. |
Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
EP3395835B1
(en)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
WO2017117311A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
SG10202103844WA
(en)
|
2015-12-30 |
2021-06-29 |
Genentech Inc |
Use of tryptophan derivatives for protein formulations
|
ES2861587T3
(es)
|
2015-12-31 |
2021-10-06 |
Progastrine Et Cancers S A R L |
Composiciones y métodos para detectar y tratar el cáncer de esófago
|
MX2018008175A
(es)
|
2015-12-31 |
2019-02-20 |
Syncerus S A R L |
Composiciones y metodos para evaluar el riesgo de ocurrencia de cancer.
|
CN108700588A
(zh)
|
2015-12-31 |
2018-10-23 |
普莱戈斯瑞恩癌症有限责任公司 |
用于检测和治疗胃癌的组合物和方法
|
CA3194356A1
(en)
|
2015-12-31 |
2017-07-06 |
Progastrine Et Cancers S.A R.L. |
Compositions and methods for detecting and treating ovarian cancer
|
US11103589B2
(en)
|
2016-01-08 |
2021-08-31 |
Apg Therapeutics, Inc. |
Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
DK3411404T3
(da)
|
2016-02-03 |
2023-01-30 |
Amgen Res Munich Gmbh |
Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
US11262359B2
(en)
|
2016-02-05 |
2022-03-01 |
NanoView Biosciences, Inc. |
Detection of exosomes having surface markers
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
US11472877B2
(en)
|
2016-03-04 |
2022-10-18 |
Alector Llc |
Anti-TREM1 antibodies and methods of use thereof
|
JP7157981B2
(ja)
|
2016-03-07 |
2022-10-21 |
チャールストンファーマ, エルエルシー |
抗ヌクレオリン抗体
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
CN109069640B
(zh)
|
2016-03-14 |
2023-10-03 |
中外制药株式会社 |
用于癌症治疗的诱导细胞损伤的治疗药物
|
US10870701B2
(en)
|
2016-03-15 |
2020-12-22 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
CA3016552A1
(en)
|
2016-03-15 |
2017-09-21 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
WO2017158101A1
(en)
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
IL261261B2
(en)
|
2016-03-17 |
2024-04-01 |
Numab Therapeutics AG |
Antibodies against TNF-ALPHA and their functional fragments
|
SI3219726T1
(sl)
|
2016-03-17 |
2021-02-26 |
Tillotts Pharma Ag |
Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
|
PT3219727T
(pt)
|
2016-03-17 |
2021-01-21 |
Tillotts Pharma Ag |
Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
|
JP7184746B2
(ja)
|
2016-03-17 |
2022-12-06 |
ヌマブ イノヴェイション アーゲー |
抗TNFα抗体およびそれらの機能的断片
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
EP3436477A2
(en)
|
2016-03-29 |
2019-02-06 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
CA3019560A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
SG11201809024UA
(en)
|
2016-04-22 |
2018-11-29 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
BR112018073133A2
(pt)
|
2016-05-10 |
2019-04-30 |
Genentech Inc |
métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Hdac抑制劑與pd-l1抑制劑之組合治療
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
MX2018014175A
(es)
|
2016-05-17 |
2020-02-07 |
Abbvie Biotherapeutics Inc |
Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
|
US11649291B2
(en)
|
2016-05-24 |
2023-05-16 |
Insmed Incorporated |
Antibodies and methods of making same
|
KR20190012201A
(ko)
|
2016-05-26 |
2019-02-08 |
메르크 파텐트 게엠베하 |
암 치료용 pd-1 / pd-l1 억제제
|
MY195089A
(en)
|
2016-05-27 |
2023-01-10 |
Agenus Inc |
Anti-Tim-3 Antibodies and Methods of use thereof
|
CR20180605A
(es)
|
2016-05-27 |
2020-01-13 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-cd40 y sus usos
|
WO2017205745A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
BR112018075626A2
(pt)
|
2016-06-08 |
2019-03-19 |
Abbvie Inc. |
anticorpos anti-b7-h3 e conjugados de fármaco anticorpo
|
KR101996019B1
(ko)
|
2016-06-13 |
2019-07-03 |
아이-맵 |
항-pd-l1 항체 및 이것의 사용
|
JP7237344B2
(ja)
|
2016-06-15 |
2023-03-13 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
インフルエンザウイルス血球凝集素タンパク質及びその使用
|
CN109689685A
(zh)
|
2016-07-08 |
2019-04-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体及其使用方法
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
US11312745B2
(en)
|
2016-07-22 |
2022-04-26 |
Amgen Inc. |
Methods of purifying Fc-containing proteins
|
KR102534568B1
(ko)
|
2016-07-22 |
2023-05-18 |
다나-파버 캔서 인스티튜트 인크. |
글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법
|
US20190330318A1
(en)
|
2016-07-25 |
2019-10-31 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
TWI786054B
(zh)
|
2016-07-29 |
2022-12-11 |
台灣浩鼎生技股份有限公司 |
人類抗體、醫藥組合物、及其方法
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
JP7148493B2
(ja)
|
2016-08-01 |
2022-10-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
副甲状腺ホルモン受容体1(pth1r)抗体およびその使用
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
CN109689102A
(zh)
|
2016-08-12 |
2019-04-26 |
基因泰克公司 |
Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
EP3507305A1
(en)
|
2016-09-02 |
2019-07-10 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
US20190233505A1
(en)
|
2016-09-06 |
2019-08-01 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating or preventing zika virus infection
|
CN109661241A
(zh)
|
2016-09-06 |
2019-04-19 |
中外制药株式会社 |
使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
|
EP3510046A4
(en)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
SG10201914120XA
(en)
|
2016-09-14 |
2020-03-30 |
Abbvie Biotherapeutics Inc |
Anti-pd-1(cd279) antibodies
|
KR101953706B1
(ko)
|
2016-09-19 |
2019-03-05 |
아이-맵 |
항-gm-csf 항체 및 이것의 사용
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
AU2017330346A1
(en)
|
2016-09-21 |
2019-02-21 |
Nextcure, Inc. |
Antibodies for Siglec-15 and methods of use thereof
|
EP4360714A2
(en)
|
2016-09-21 |
2024-05-01 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
SG10201913032TA
(en)
|
2016-09-23 |
2020-02-27 |
Teva Pharmaceuticals Int Gmbh |
Treating refractory migraine
|
BR112019005944A2
(pt)
|
2016-09-28 |
2019-06-11 |
Musc Foudation For Res Development |
anticorpos que se ligam à interleucina 2 e usos dos mesmos
|
MX2019003603A
(es)
|
2016-09-29 |
2019-08-01 |
Genentech Inc |
Terapia de combinacion con un inhibidor de mek, un inhibidor del eje pd-1 y un taxano.
|
CN110383068A
(zh)
|
2016-10-03 |
2019-10-25 |
雅培实验室 |
评估患者样品中uch-l1状态的改进方法
|
IL265762B2
(en)
|
2016-10-06 |
2024-04-01 |
Merck Patent Gmbh |
Dosing regimen of avolumab for cancer treatment
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
CN117586403A
(zh)
|
2016-10-11 |
2024-02-23 |
艾吉纳斯公司 |
抗lag-3抗体及其使用方法
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
ES2908239T3
(es)
|
2016-10-28 |
2022-04-28 |
Astute Medical Inc |
Uso de anticuerpos contra timp-2 para la mejora de la función renal
|
CA3041843A1
(en)
|
2016-11-02 |
2018-05-11 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
CA3040812A1
(en)
|
2016-11-04 |
2018-05-11 |
Novimmune Sa |
Anti-cd19 antibodies and methods of use thereof
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
WO2018090052A1
(en)
|
2016-11-14 |
2018-05-17 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
AU2017361549B2
(en)
|
2016-11-21 |
2023-12-21 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
CA3082255A1
(en)
|
2016-11-23 |
2020-06-10 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
CN110214151A
(zh)
|
2016-11-28 |
2019-09-06 |
中外制药株式会社 |
具有可调节的配体结合活性的配体结合分子
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
EA201991383A1
(ru)
|
2016-12-07 |
2019-12-30 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
RS60664B1
(sr)
|
2016-12-15 |
2020-09-30 |
Abbvie Biotherapeutics Inc |
Anti-ox40 antitela i njihove upotrebe
|
CA3047557A1
(en)
|
2016-12-19 |
2018-06-28 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
JP6982075B2
(ja)
|
2016-12-27 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規のビオチン特異的モノクローナル抗体およびその使用
|
EP3562841A1
(en)
|
2016-12-27 |
2019-11-06 |
H. Hoffnabb-La Roche Ag |
Novel biotin-specific monoclonal antibody and use thereof
|
KR102413013B1
(ko)
|
2016-12-27 |
2022-06-23 |
에프. 호프만-라 로슈 아게 |
신규한 비오틴-특이적 단일클론 항체 및 그 용도
|
CN110291105B
(zh)
|
2017-01-05 |
2024-03-01 |
奈特里斯药物公司 |
导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗
|
US11773182B2
(en)
|
2017-01-05 |
2023-10-03 |
The Johns Hopkins University |
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
|
WO2018128454A1
(ko)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
항 α-SYN 항체 및 그 용도
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
BR112019013238A2
(pt)
|
2017-01-20 |
2020-02-11 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anticorpos anti-pd-1 e usos dos mesmos
|
WO2018137598A1
(en)
|
2017-01-24 |
2018-08-02 |
I-Mab |
Anti-cd73 antibodies and uses thereof
|
CA3051484A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
CA3052095A1
(en)
|
2017-01-30 |
2018-08-02 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
JP7068323B2
(ja)
|
2017-02-02 |
2022-05-16 |
エフ.ホフマン-ラ ロシュ アーゲー |
少なくとも2種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
|
KR20240038148A
(ko)
|
2017-02-07 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
KR20240044544A
(ko)
|
2017-03-03 |
2024-04-04 |
씨젠 인크. |
글리칸-상호작용 화합물 및 사용 방법
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
CA3057808A1
(en)
|
2017-03-24 |
2018-09-27 |
Zenyaku Kogyo Co., Ltd. |
Anti-igm/b cell surface antigen bispecific antibody
|
BR112019019939A2
(pt)
|
2017-03-30 |
2020-04-28 |
Merck Patent Gmbh |
combinação de anticorpo anti-pd-l1 e um inibidor de dna-pk para tratamento de câncer
|
CA3058265C
(en)
|
2017-03-30 |
2023-03-14 |
Progastrine Et Cancers S.A R.L. |
Compositions and methods for treating lung cancer
|
CN110662769B
(zh)
|
2017-03-30 |
2023-10-20 |
普莱戈斯瑞恩癌症有限责任公司 |
使用前胃泌素结合分子检测和治疗前列腺癌的组合物和方法
|
WO2018181870A1
(ja)
|
2017-03-31 |
2018-10-04 |
公立大学法人奈良県立医科大学 |
血液凝固第viii因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ix因子異常症の予防および/または治療に用いられる医薬組成物
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
CN110709103B
(zh)
|
2017-04-05 |
2024-02-02 |
机敏医药股份有限公司 |
用于生物学样品中具有改善的性能的timp2的测定法
|
CA3058652A1
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
JOP20190243A1
(ar)
|
2017-04-12 |
2019-10-13 |
Medimmune Llc |
علاج الربو بجسم مضاد لـ tslp
|
EP3609921A2
(en)
|
2017-04-13 |
2020-02-19 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
JP7344797B2
(ja)
|
2017-04-15 |
2023-09-14 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
|
JP2020517242A
(ja)
|
2017-04-21 |
2020-06-18 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ApoC3抗体およびその使用方法
|
CN110799529A
(zh)
|
2017-04-22 |
2020-02-14 |
免疫治疗有限公司 |
改良lamp构建物
|
EP3615052B1
(en)
|
2017-04-27 |
2023-01-25 |
The University of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
EP3617316A4
(en)
|
2017-04-27 |
2020-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
|
BR112019022476A2
(pt)
|
2017-04-28 |
2020-05-12 |
Abbott Laboratories |
Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
|
WO2018204363A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
US20200087365A1
(en)
|
2017-05-02 |
2020-03-19 |
Immunomic Therapeutics, Inc |
Improved lamp constructs comprising cancer antigens
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
EP3618864A1
(en)
|
2017-05-05 |
2020-03-11 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2018213316A1
(en)
|
2017-05-16 |
2018-11-22 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
US10914729B2
(en)
|
2017-05-22 |
2021-02-09 |
The Trustees Of Princeton University |
Methods for detecting protein binding sequences and tagging nucleic acids
|
US11530273B2
(en)
|
2017-05-23 |
2022-12-20 |
Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
|
JP7416625B2
(ja)
|
2017-05-25 |
2024-01-17 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
|
CA3065008A1
(en)
|
2017-05-26 |
2018-11-29 |
Novimmune Sa |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
JP7269183B2
(ja)
|
2017-05-30 |
2023-05-08 |
アボット・ラボラトリーズ |
心臓トロポニンiを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
|
CN111148762A
(zh)
|
2017-05-31 |
2020-05-12 |
斯特库伯株式会社 |
免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
AU2018277545A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
AU2018288854A1
(en)
|
2017-06-20 |
2019-11-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
TW201920266A
(zh)
|
2017-07-14 |
2019-06-01 |
美商輝瑞大藥廠 |
Madcam 抗體
|
EP3655034A1
(en)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CA3071105A1
(en)
|
2017-07-27 |
2019-01-31 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
JP7299160B2
(ja)
|
2017-08-03 |
2023-06-27 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
CR20190485A
(es)
|
2017-08-03 |
2020-02-10 |
Alector Llc |
Anticuerpos anti-trem2 y métodos para utilizarlos
|
US20210346513A1
(en)
|
2017-08-04 |
2021-11-11 |
Amgen Inc. |
Method of conjugation of cys-mabs
|
US11585014B2
(en)
|
2017-08-21 |
2023-02-21 |
Adagene Inc. |
Dynamic human antibody light chain libraries
|
KR20200038996A
(ko)
|
2017-08-21 |
2020-04-14 |
아다진 인크. |
동적 인간 중쇄 항체 라이브러리
|
EP3679070A1
(en)
|
2017-09-07 |
2020-07-15 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
BR112020005737A2
(pt)
|
2017-09-22 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
anticorpo recombinante multivalente e uso do mesmo, kit e método para detectar um antígeno
|
TW201922780A
(zh)
*
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
WO2019078344A1
(ja)
|
2017-10-20 |
2019-04-25 |
学校法人兵庫医科大学 |
抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
WO2019083904A1
(en)
|
2017-10-23 |
2019-05-02 |
Chan Zuckerberg Biohub, Inc. |
AFUCOSYLATED IGG FC GLYCANES MEASUREMENT AND METHODS OF TREATMENT THEREOF
|
EP3700567A4
(en)
|
2017-10-26 |
2021-09-29 |
The Regents of The University of California |
INHIBITION OF OXIDATION SPECIFIC EPITOPES FOR TREATMENT OF ISCHEMIC REPERFUSION DAMAGE
|
WO2019087115A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
WO2019089594A1
(en)
|
2017-10-31 |
2019-05-09 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
EP3717069A1
(en)
|
2017-11-27 |
2020-10-07 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
TWI818934B
(zh)
|
2017-11-28 |
2023-10-21 |
日商中外製藥股份有限公司 |
可調整配體結合活性的配體結合分子
|
US11365250B2
(en)
|
2017-11-29 |
2022-06-21 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cancer therapy
|
AU2018379320B2
(en)
|
2017-12-05 |
2023-06-15 |
Progastrine Et Cancers S.À R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
CA3083783A1
(en)
|
2017-12-06 |
2019-06-13 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
EP3721233A2
(en)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
JP7379165B2
(ja)
|
2017-12-09 |
2023-11-14 |
アボット・ラボラトリーズ |
Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
|
MX2020006007A
(es)
|
2017-12-11 |
2020-08-17 |
Amgen Inc |
Procedimiento de fabricacion continuo para productos de anticuerpos biespecificos.
|
CA3085861C
(en)
|
2017-12-20 |
2023-09-26 |
Harbour Biomed (Shanghai) Co., Ltd |
Antibodies binding ctla-4 and uses thereof
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Tigitに対する単一ドメイン抗体及びその変異体
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
CN112041341B
(zh)
|
2017-12-28 |
2024-05-24 |
机敏医药股份有限公司 |
Ccl14的抗体和检测
|
CA3078849A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
SG11202005323SA
(en)
|
2018-01-12 |
2020-07-29 |
Bristol Myers Squibb Co |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
BR112020013621A2
(pt)
|
2018-01-12 |
2020-12-01 |
Amgen Inc. |
anticorpos contra pac1 e usos dos mesmos
|
SG11202004233UA
(en)
|
2018-01-15 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against pd-1
|
BR112020013405A2
(pt)
|
2018-01-25 |
2020-12-01 |
Acm Biolabs Pte Ltd. |
polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ecs前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
JP7458790B2
(ja)
|
2018-01-31 |
2024-04-01 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
EP3759141A1
(en)
|
2018-02-26 |
2021-01-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
SG11202008271QA
(en)
|
2018-02-27 |
2020-09-29 |
Ecs Progastrin Sa |
Progastrin as a biomarker for immunotherapy
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
WO2019177690A1
(en)
|
2018-03-12 |
2019-09-19 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
CA3093330A1
(en)
|
2018-03-14 |
2019-09-19 |
Novimmune Sa |
Anti-cd3 epsilon antibodies and methods of use thereof
|
KR20200130831A
(ko)
|
2018-03-14 |
2020-11-20 |
베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 |
항-클라우딘 18.2 항체
|
EP3768314A4
(en)
|
2018-03-21 |
2022-01-05 |
ALX Oncology Inc. |
ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
HUE062414T2
(hu)
|
2018-03-26 |
2023-10-28 |
Glycanostics S R O |
Eszközök és eljárások fehérje glikoprofilozására
|
EP3772926A1
(en)
*
|
2018-03-26 |
2021-02-17 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
JP7346790B2
(ja)
|
2018-03-30 |
2023-09-20 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Lag‐3に対する単一ドメイン抗体およびその使用
|
KR20200139219A
(ko)
|
2018-04-02 |
2020-12-11 |
브리스톨-마이어스 스큅 컴퍼니 |
항-trem-1 항체 및 이의 용도
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
US20210230255A1
(en)
|
2018-04-27 |
2021-07-29 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
KR20210006405A
(ko)
|
2018-05-04 |
2021-01-18 |
메르크 파텐트 게엠베하 |
암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
|
US11970532B2
(en)
|
2018-05-10 |
2024-04-30 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
JP2021523185A
(ja)
|
2018-05-15 |
2021-09-02 |
イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. |
アレルゲンを含む改善されたlamp構築物
|
JP7421500B2
(ja)
|
2018-05-18 |
2024-01-24 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体でループスを治療する安全かつ有効な方法
|
KR20210010996A
(ko)
|
2018-05-21 |
2021-01-29 |
추가이 세이야쿠 가부시키가이샤 |
유리 용기에 봉입된 동결건조 제제
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
MA52753A
(fr)
|
2018-05-25 |
2021-04-21 |
Alector Llc |
Anticorps anti-sirpa et leurs procédés d'utilisation
|
EP3803332A1
(en)
|
2018-06-01 |
2021-04-14 |
NanoView Biosciences, Inc. |
Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
|
MA52783A
(fr)
|
2018-06-05 |
2021-04-14 |
Amgen Inc |
Modulation de la phagocytose cellulaire dépendant de l'anticorps
|
BR112020024919A2
(pt)
|
2018-06-08 |
2021-03-09 |
Alector Llc |
Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica
|
AU2019288677A1
(en)
|
2018-06-21 |
2021-01-14 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
MX2020013923A
(es)
|
2018-06-29 |
2021-03-29 |
Apitbio Inc |
Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
|
EP3820888A4
(en)
|
2018-07-13 |
2022-04-27 |
Nanjing Legend Biotech Co., Ltd. |
CO-RECEPTOR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASES
|
HUE061841T2
(hu)
|
2018-07-13 |
2023-08-28 |
Alector Llc |
Anti-sortilin antitestek és felhasználásuk módszerei
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
AU2019306165A1
(en)
|
2018-07-20 |
2021-02-25 |
Pierre Fabre Medicament |
Receptor for vista
|
EP3830123A1
(en)
|
2018-07-27 |
2021-06-09 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
MX2021001221A
(es)
|
2018-07-30 |
2021-06-23 |
Amgen Res Munich Gmbh |
Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
|
EP3829633A1
(en)
|
2018-08-03 |
2021-06-09 |
Amgen Research (Munich) GmbH |
Antibody constructs for cldn18.2 and cd3
|
WO2020033485A1
(en)
|
2018-08-08 |
2020-02-13 |
Genentech, Inc. |
Use of tryptophan derivatives and l-methionine for protein formulation
|
JP2021534779A
(ja)
|
2018-08-27 |
2021-12-16 |
アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク |
抗体構築物がプレロードされた凍結保存nk細胞
|
AU2019339895A1
(en)
|
2018-09-11 |
2021-03-11 |
Amgen Inc. |
Methods of modulating antibody-dependent cell-mediated cytotoxicity
|
CN112996539A
(zh)
|
2018-09-12 |
2021-06-18 |
Acm生物实验室私人有限公司 |
包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
PL3857230T3
(pl)
|
2018-09-21 |
2023-10-16 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne dla potrójnie ujemnego raka piersi
|
WO2020065532A1
(en)
|
2018-09-24 |
2020-04-02 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
KR20210066837A
(ko)
|
2018-09-26 |
2021-06-07 |
메르크 파텐트 게엠베하 |
암 치료를 위한 pd-1 안타고니스트, atr 억제제 및 백금화제의 조합
|
WO2020069303A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Antibodies against soluble bcma
|
EP3860713A2
(en)
|
2018-10-03 |
2021-08-11 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
CA3114802A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
WO2020078905A1
(en)
|
2018-10-15 |
2020-04-23 |
Merck Patent Gmbh |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
MX2021004819A
(es)
|
2018-11-02 |
2021-06-08 |
Annexon Inc |
Composiciones y metodos para tratar lesiones cerebrales.
|
CN113260626A
(zh)
|
2018-11-05 |
2021-08-13 |
豪夫迈·罗氏有限公司 |
在原核宿主细胞中产生双链蛋白质的方法
|
US20220011301A1
(en)
|
2018-11-16 |
2022-01-13 |
Roche Diagnostics Operations, Inc. |
Streptavidin-coated solid phases with a member of a binding pair
|
WO2020117988A1
(en)
|
2018-12-04 |
2020-06-11 |
Tolero Pharmaceuticals, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
WO2020118293A2
(en)
|
2018-12-07 |
2020-06-11 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
KR20210116525A
(ko)
|
2019-01-14 |
2021-09-27 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신으로 암을 치료하는 방법
|
KR20210118115A
(ko)
|
2019-01-23 |
2021-09-29 |
제넨테크, 인크. |
진핵 숙주 세포에서 다합체 단백질을 생산하는 방법
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
EP3917515A1
(en)
|
2019-01-29 |
2021-12-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Treating the causative agent in adhesiogenesis
|
AU2019427766A1
(en)
|
2019-01-30 |
2021-09-16 |
Nomocan Pharmaceuticals Llc |
Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
AU2020221821A1
(en)
|
2019-02-13 |
2021-08-26 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
CA3131036A1
(en)
|
2019-02-22 |
2020-08-27 |
Wuhan Yzy Biopharma Co., Ltd. |
Cd3 antigen-binding fragment and application thereof
|
CA3130303A1
(en)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
KR20210133237A
(ko)
|
2019-02-27 |
2021-11-05 |
제넨테크, 인크. |
항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
|
CN113508140A
(zh)
|
2019-02-28 |
2021-10-15 |
学校法人顺天堂 |
与切断型的突变型Calreticulin结合的抗体以及骨髄增殖性肿瘤的诊断、预防或治疗药
|
JP7379654B2
(ja)
|
2019-03-15 |
2023-11-14 |
カーティザン セラピューティクス,インコーポレーテッド |
抗bcmaキメラ抗原受容体
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
EP3947471A4
(en)
|
2019-03-27 |
2023-03-15 |
The Trustees of The University of Pennsylvania |
TN-MUC1 CHIMERIC ANTIGEN RECEPTOR (CAR) T-LYMPHOCYTE THERAPY
|
EP3947442A2
(en)
|
2019-03-28 |
2022-02-09 |
Danisco US Inc. |
Engineered antibodies
|
BR112021020204A2
(pt)
|
2019-04-10 |
2021-12-07 |
Chugai Pharmaceutical Co Ltd |
Método para purificar anticorpo com região fc modificada
|
WO2020213665A1
(ja)
|
2019-04-17 |
2020-10-22 |
国立大学法人広島大学 |
Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
|
AU2020263959A1
(en)
|
2019-04-24 |
2021-11-25 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
JP2022530674A
(ja)
|
2019-05-03 |
2022-06-30 |
ジェネンテック, インコーポレイテッド |
抗pd-l1抗体を用いたがんの処置方法
|
CA3138241A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
US20200369759A1
(en)
|
2019-05-23 |
2020-11-26 |
Fibrogen, Inc. |
Methods of treatment of muscular dystrophies
|
SG11202112926YA
(en)
|
2019-05-30 |
2021-12-30 |
Amgen Inc |
Engineering the hinge region to drive antibody dimerization
|
TW202112808A
(zh)
|
2019-06-05 |
2021-04-01 |
日商中外製藥股份有限公司 |
抗體切斷部位結合分子
|
EP3983520A1
(en)
|
2019-06-13 |
2022-04-20 |
Amgen, Inc |
Automated biomass-based perfusion control in the manufacturing of biologics
|
US20220363770A1
(en)
|
2019-06-28 |
2022-11-17 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
JP2022545741A
(ja)
|
2019-08-30 |
2022-10-28 |
アジェナス インコーポレイテッド |
抗cd96抗体およびその使用方法
|
EP4026846A4
(en)
|
2019-09-03 |
2023-09-13 |
Bio-Thera Solutions, Ltd. |
ANTI-TIGITE IMMUNOSUPPRESSANT AND USE THEREOF
|
MX2022002738A
(es)
|
2019-09-04 |
2022-06-27 |
Genentech Inc |
Agentes de union a cd8 y uso de los mismos.
|
EP4028416A1
(en)
|
2019-09-10 |
2022-07-20 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
AU2020345913A1
(en)
|
2019-09-12 |
2022-02-24 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
JP2022549504A
(ja)
|
2019-09-26 |
2022-11-25 |
エスティーキューブ アンド カンパニー |
グリコシル化ctla-4に対して特異的な抗体およびその使用方法
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
EP4041768A1
(en)
|
2019-10-09 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
CN115175680A
(zh)
|
2019-10-18 |
2022-10-11 |
加利福尼亚大学董事会 |
Plxdc激活剂及其用于治疗血管病症的用途
|
JP2022551732A
(ja)
|
2019-10-18 |
2022-12-13 |
イミュノミック セラピューティックス, インコーポレイテッド |
がん抗原を含む改良lamp構築物
|
AU2020375161A1
(en)
|
2019-11-01 |
2022-05-19 |
Ares Trading S.A. |
Combined inhibition of PD-1, TGFβ and ATM together with radiotherapy for the treatment of cancer
|
US20220401481A1
(en)
|
2019-11-01 |
2022-12-22 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
JP2023502585A
(ja)
|
2019-11-05 |
2023-01-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌の治療のための、PD-1、TGFβ、及びTIGITの組み合わせ阻害
|
AU2020378330A1
(en)
|
2019-11-06 |
2022-05-12 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
WO2021092355A1
(en)
|
2019-11-08 |
2021-05-14 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-igg molecules
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
EP4061838A1
(en)
|
2019-11-19 |
2022-09-28 |
Amgen Inc. |
Novel multispecific antibody format
|
EP3825330A1
(en)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117 antibodies and methods of use thereof
|
KR20220110537A
(ko)
|
2019-12-05 |
2022-08-08 |
알렉터 엘엘씨 |
항-trem2 항체 사용 방법
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
KR20220113414A
(ko)
|
2019-12-09 |
2022-08-12 |
제넨테크, 인크. |
항-pd-l1 항체 제제
|
BR112022011337A2
(pt)
|
2019-12-12 |
2022-08-23 |
Alector Llc |
Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
WO2021130383A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
US20230090552A1
(en)
|
2020-01-08 |
2023-03-23 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CN116650628A
(zh)
|
2020-01-31 |
2023-08-29 |
基因泰克公司 |
用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
CA3167851A1
(en)
|
2020-02-24 |
2021-09-02 |
Francesca CIGNARELLA |
Methods of use of anti-trem2 antibodies
|
US20230126689A1
(en)
|
2020-03-06 |
2023-04-27 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
IL296241A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Compositions and methods for immunotherapy for npm1c-positive cancer
|
US20230146593A1
(en)
|
2020-03-12 |
2023-05-11 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
|
CA3175275A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
EP4129333A4
(en)
|
2020-03-27 |
2024-06-12 |
Photoq3 Inc |
PHARMACEUTICAL MEDICINAL PRODUCT FOR THE DESTROYING OF TUMOR CELLS
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
EP4130035A4
(en)
|
2020-03-31 |
2024-06-26 |
Bio Thera Solutions Ltd |
ANTIBODIES AND FUSION PROTEIN FOR THE TREATMENT OF CORONAVIRUS AND USE THEREOF
|
KR20230005848A
(ko)
|
2020-04-03 |
2023-01-10 |
알렉터 엘엘씨 |
항-trem2 항체의 사용 방법
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
EP4134099A4
(en)
|
2020-04-06 |
2024-05-29 |
Photoq3 Inc |
MEDICINES TO KILL TUMOR CELLS
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
AU2021262744A1
(en)
|
2020-04-27 |
2022-10-06 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
AU2021263754A1
(en)
|
2020-04-27 |
2022-12-01 |
Ensoma, Inc. |
Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
MX2022014636A
(es)
|
2020-05-19 |
2023-02-23 |
Amgen Inc |
Construcciones de unión a mageb2.
|
WO2021235537A1
(ja)
|
2020-05-22 |
2021-11-25 |
中外製薬株式会社 |
凝固第viii因子(f.viii)機能代替活性を有する物質を中和する抗体
|
EP3915641A1
(en)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
MX2022014902A
(es)
|
2020-05-29 |
2023-01-04 |
Amgen Inc |
Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3.
|
WO2021247908A1
(en)
|
2020-06-03 |
2021-12-09 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
JP2023531200A
(ja)
|
2020-06-18 |
2023-07-21 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体及びpd-1軸結合アンタゴニストを用いた治療
|
JPWO2021261546A1
(ko)
|
2020-06-24 |
2021-12-30 |
|
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
JP2023534987A
(ja)
|
2020-07-24 |
2023-08-15 |
アムジエン・インコーポレーテツド |
Sars-cov2スパイクタンパク質に由来する免疫原
|
TW202220694A
(zh)
|
2020-07-28 |
2022-06-01 |
日商中外製藥股份有限公司 |
含有新穎之改變型抗體、具有針套的帶針頭預填充注射器製劑
|
AU2021317974A1
(en)
|
2020-07-31 |
2023-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
|
WO2022026699A1
(en)
|
2020-07-31 |
2022-02-03 |
Genentech, Inc. |
Anti-integrin beta7 antibody formulations and devices
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
CA3188349A1
(en)
|
2020-08-04 |
2022-02-10 |
A. Scott Muerhoff |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
CN114057877A
(zh)
|
2020-08-07 |
2022-02-18 |
百奥泰生物制药股份有限公司 |
抗pd-l1抗体及其应用
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2023538897A
(ja)
|
2020-08-20 |
2023-09-12 |
アムジエン・インコーポレーテツド |
Fab領域中に非標準的なジスルフィドを有する抗原結合タンパク質
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
CN116322763A
(zh)
|
2020-08-27 |
2023-06-23 |
学校法人顺天堂 |
抗切断型突变calr-cd3双特异性抗体及医药组合物
|
CN116113707A
(zh)
|
2020-08-31 |
2023-05-12 |
基因泰克公司 |
用于产生抗体的方法
|
JP2023540082A
(ja)
|
2020-09-04 |
2023-09-21 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
SARS-CoV-2ワクチン及び抗体
|
WO2022056490A1
(en)
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Chimeric antigen receptors for treatment of cancer
|
EP4225786A2
(en)
|
2020-10-07 |
2023-08-16 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
EP4225792A1
(en)
|
2020-10-08 |
2023-08-16 |
Affimed GmbH |
Trispecific binders
|
US12006550B2
(en)
|
2020-10-12 |
2024-06-11 |
University Of South Carolina |
Targeting treatment for ADAM30 in pathological cells
|
EP4229081A1
(en)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
EP4237441A1
(en)
|
2020-11-02 |
2023-09-06 |
F. Hoffmann-La Roche AG |
Sars-cov-2 nucleocapsid antibodies
|
AU2021370991A1
(en)
|
2020-11-02 |
2023-06-22 |
Ares Trading S.A. |
Combination treatment of cancer
|
WO2022090527A1
(en)
|
2020-11-02 |
2022-05-05 |
Ares Trading S.A. |
Combination treatment of cancer
|
AR124019A1
(es)
|
2020-11-06 |
2023-02-01 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen a cd3
|
EP4240770A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Research (Munich) GmbH |
Polypeptide constructs selectively binding to cldn6 and cd3
|
IL301926A
(en)
|
2020-11-06 |
2023-06-01 |
Amgen Inc |
Antigen binding domain with reduced cleavage rate
|
EP4242232A1
(en)
|
2020-11-06 |
2023-09-13 |
Bio-Thera Solutions, Ltd. |
Bispecific antibody and use thereof
|
MX2023005322A
(es)
|
2020-11-06 |
2023-08-29 |
Amgen Inc |
Moleculas de union a antigeno biespecificas con multiples dianas de selectividad aumentada.
|
US20240002545A1
(en)
|
2020-11-10 |
2024-01-04 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
WO2022100694A1
(zh)
|
2020-11-12 |
2022-05-19 |
迈威(上海)生物科技股份有限公司 |
抗体及其制备方法
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
CA3211581A1
(en)
|
2021-03-10 |
2022-09-15 |
Ellen WU |
Immunomodulatory molecules and uses thereof
|
MX2023010491A
(es)
|
2021-03-12 |
2023-09-18 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis.
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
WO2022197776A1
(en)
|
2021-03-16 |
2022-09-22 |
Magenta Therapeutics, Inc. |
Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
|
WO2022200389A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
JP2024512574A
(ja)
|
2021-03-22 |
2024-03-19 |
ノビミューン エスアー |
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
WO2022212831A1
(en)
|
2021-04-02 |
2022-10-06 |
Amgen Inc. |
Mageb2 binding constructs
|
CN117202897A
(zh)
|
2021-04-09 |
2023-12-08 |
基因泰克公司 |
使用raf抑制剂和pd-1轴抑制剂的组合疗法
|
JP2024518710A
(ja)
|
2021-04-12 |
2024-05-02 |
エイシーエム バイオラブズ プライベート リミテッド |
可溶性封入ポリヌクレオチドとイオン化可能脂質とを含むポリマーソームならびにその作製および使用方法
|
EP4326761A1
(en)
|
2021-04-20 |
2024-02-28 |
Amgen Inc. |
Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
|
WO2022232376A1
(en)
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
IL308163A
(en)
|
2021-05-03 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting HER2
|
MX2023012974A
(es)
|
2021-05-04 |
2023-11-15 |
Regeneron Pharmaceuticals Inc |
Agonistas multiespecificos de receptores del fgf21 y sus usos.
|
MX2023012931A
(es)
|
2021-05-06 |
2023-11-13 |
Amgen Res Munich Gmbh |
Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.
|
EP4334354A1
(en)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
EP4341699A1
(en)
|
2021-05-18 |
2024-03-27 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
IL308818A
(en)
|
2021-05-25 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting EGFR
|
CA3220380A1
(en)
|
2021-06-07 |
2022-12-15 |
Rinat ZAYNAGETDINOV |
Combination treatment of cancer
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
WO2023010118A1
(en)
|
2021-07-29 |
2023-02-02 |
Vor Biopharma Inc. |
Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
|
WO2023007023A1
(en)
|
2021-07-30 |
2023-02-02 |
Affimed Gmbh |
Duplexbodies
|
EP4380604A1
(en)
|
2021-08-05 |
2024-06-12 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
WO2023018803A1
(en)
|
2021-08-10 |
2023-02-16 |
Byomass Inc. |
Anti-gdf15 antibodies, compositions and uses thereof
|
CA3229526A1
(en)
|
2021-08-16 |
2023-02-23 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
WO2023023489A2
(en)
|
2021-08-17 |
2023-02-23 |
Hemogenyx Pharmaceuticals Llc |
Bispecific anti-flt3/cd3 antibodies and methods of use
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023034569A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
AU2022339819A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
JPWO2023048231A1
(ko)
|
2021-09-24 |
2023-03-30 |
|
|
WO2023051663A1
(zh)
|
2021-09-30 |
2023-04-06 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CN118043031A
(zh)
|
2021-10-04 |
2024-05-14 |
诺华股份有限公司 |
表面活性剂稳定剂
|
TW202323810A
(zh)
|
2021-10-08 |
2023-06-16 |
日商中外製藥股份有限公司 |
預填充式注射器製劑的調製方法
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
WO2023072904A1
(en)
|
2021-10-26 |
2023-05-04 |
F. Hoffmann-La Roche Ag |
Monoclonal antibodies specific for sars-cov-2 rbd
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
AU2022383057A1
(en)
|
2021-11-05 |
2024-05-16 |
Abviro Llc |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
CA3238936A1
(en)
|
2021-11-24 |
2023-06-01 |
Wayne A. Marasco |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023111168A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
A novel antibody for detection of amyloid beta 42 (aβ42)
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
EP4245772A1
(en)
|
2022-03-18 |
2023-09-20 |
Netris Pharma |
Anti-netrin-1 antibody to treat liver inflammation
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
EP4249509A1
(en)
|
2022-03-22 |
2023-09-27 |
Netris Pharma |
Anti-netrin-1 antibody against arthritis-associated pain
|
WO2023186968A1
(en)
|
2022-03-29 |
2023-10-05 |
Netris Pharma |
Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023235415A1
(en)
|
2022-06-01 |
2023-12-07 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024038165A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Ltd |
T cell receptor fusion proteins specific for mage a4
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
WO2024097441A1
(en)
|
2022-11-02 |
2024-05-10 |
Kira Pharmaceuticals (Us) Llc |
Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
|
WO2024097796A1
(en)
|
2022-11-02 |
2024-05-10 |
Kira Pharmaceuticals (Us) Llc |
Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|